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ABBREVIATIONS 
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SUMMARY 
 
Glioblastoma multiforme (GBM) is the most frequent and aggressive intracranial tumour in humans. The 
prognosis of GBM patients remains unfavourable even after aggressive treatments based on multiple 
approaches, due to the high proliferation rate, migrating-invasive properties, and resistance to therapeutic 
intervention. The introduction of the alkylating agent TMZ in glioblastoma therapy has improved patient 
survival, but drug resistance mechanisms limit its benefits.  
The aim of this study was to provide a contribution to the understanding of the malignant and 
chemoresistance properties in GBM by focusing on the role of the bioactive sphingoid molecules ceramide 
and S1P, which act as antagonists in regulating cell properties and survival.  
Accumulating literature indicates that ceramide is a tumour suppressor sphingolipid, able to induce 
antiproliferative and apoptotic responses, and that it is able to act as a major player in the mechanism of 
action of many chemotherapeutic drugs. We demonstrated that the treatment of T98G human glioblastoma 
cells with cytotoxic TMZ concentrations results in a significant increase in intracellular ceramide, which in 
turn promotes cell death. On the other hand, TMZ is not able to induce ceramide accumulation in TMZ-
resistant glioblastoma cells (TMZ-R). These data suggest a role of ceramide as a mediator of TMZ-induced 
toxicity. 
A large amount of evidence underlines the role of S1P as an important tumour-promoting sphingolipid, acting 
predominantly in the extracellular milieu after interaction with specific G protein-coupled receptors and 
exerting opposite effects on cell survival compared to ceramide. Parallel studies demonstrated that S1P 
secretion in TMZ-R cells is functional to inhibit the cytotoxic effect of ceramide and to confer TMZ-resistant 
properties to glioblastoma cells. 
Stimulated by these findings, we next evaluated the role of sphingolipid mediators in the malignant features 
of glioblastoma stem cells (GSCs), a cell subpopulation within the tumour mass involved in the aberrant 
expansion and therapy resistance properties of glioblastomas. To this purpose we used GSCs isolated from 
the human U87-MG glioblastoma cell line and GSCs isolated from a primary culture of human glioblastoma. 
We found that both GSC models efficiently form typical neurosphere structures in mitogen-defined medium 
and express high levels of recognized cancer stem cell markers. Moreover, GSCs exhibit resistance to TMZ 
at concentrations that are cytotoxic in U87-MG, despite not expressing the DNA repair protein MGMT, a 
major contributor to TMZ-resistance. Even though a large amount of evidence underlines that S1P is able to 
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favor growth, invasion and chemotherapy resistance of glioblastoma cells, so far little is known on the 
possible role of S1P as a factor modulating GSCs malignant properties. 
Further experiments revealed that glioblastoma cells and GSCs are able to efficiently synthesize S1P and 
also to release it in the culture medium. Notably the intracellular S1P level was found much lower in GSC 
models than in the glioblastoma cell line; meanwhile the extracellular S1P level was significantly higher in 
GSC models than in U87-MG cells. These differences resulted in an extracellular S1P-intracellular S1P ratio 
at least 10 times higher in GSCs compared to U87-MG. Furthermore, this ratio is about 1:1 in both GSCs, 
thus suggesting that these cells are an efficient source of S1P in the extracellular microenvironment. 
Furthermore we found that ceramide-extracellular S1P ratio is at least 2-fold lower in GSCs than in U87-MG. 
Since S1P and ceramide exert opposing effects on cell survival, according to the “sphingolipid rheostat” 
model, this different ratio could promote GSC survival observed after TMZ treatment. 
Interestingly, enzyme activity assays excluded the presence of sphingosine kinase (SK), the enzyme 
responsible for S1P byosinthesis, in GSC medium, implicating an efficient secretion of S1P in GSCs.  
The analyses of the expression of the ABC-transporters known to be involved in S1P export (ABCG2, 
ABCA1 and ABCC1), revealed that only ABCA1 is expressed in GSCs. Notwithstanding, after ABCA1 
inhibition, no variations in S1P release was observed, suggesting that other mechanisms different from those 
known are involved.   
We also investigated the role of S1P in glioblastoma resistance to TMZ. A first interesting finding was that 
exogenously administered S1P protected U87-MG cells against TMZ cytotoxic effects. In addition, we found 
that, after co-treatment with TMZ and an inhibitor of S1P biosynthesis, GSCs became sensitive to the toxic 
effect of the drug. Of note, exogenous S1P administration was able to revert this effect. These data strongly 
support extracellular S1P as an important mediator in TMZ-resistance of GSCs.  
Furthermore, results obtained in GSCs isolated from two patients affected by glioblastoma with different 
aggressive phenotype, revealed that the extracellular release of S1P was significantly higher by cells 
isolated from the most aggressive tumour, suggesting that the release and thus the levels of extracellular 
S1P might be related to tumour aggressiveness and patient prognosis. 
In conclusion, our data implicate for the first time GSCs as an important source of S1P in the extracellular 
microenvironment, where, on its turn, S1P can act as an autocrine/paracrine messenger able to contribute to 
the GSC survival properties. A better understanding of S1P role in GSCs aggressive phenotype could 
represent a critical start point that sets the bases for the development of new compounds able to sensitize 
GSCs to chemotherapeutic treatments, thus improving survival rates in GBM patients. 
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INTRODUCTION 
 
 
1. HUMAN GLIOMAS  
 
1.1 Glioma features 
Gliomas are the most common primary brain tumours in humans and an important cause of mental 
impairment and death [1]. As central nervous system tumours, they are characterized by special features 
that differentiate them from all the other tumours. First, the distinction between benign and malignant lesions 
is less apparent than in other locations. Some glial tumours with benign histological features, such as low 
mitotic index, cell uniformity and slow growth, can infiltrate entire regions of the brain, showing a clinically 
malignant behaviour. In addition, the anatomical location of the tumour can have fatal consequences 
regardless of histological features, for instance an expanding benign tumour can lead to a condition of brain 
compression resulting in severe neurological impairment. Furthermore, even the most malignant gliomas 
rarely metastasize outside of the central nervous system [2]. 
Gliomas include a group of highly heterogeneous cancers classified, according to cell line derivation and 
differentiation morphological evidence, in: astrocytoma, oligodendroglioma, oligoastrocytoma, ependymoma 
and choroid plexus tumours [3]. Astrocytomas are the highest incidence gliomas (75% of all gliomas) [4], 
sorted by the World Health Organization (WHO) in different classes, distinguished by the presence of 
specific histological characteristics such as nuclear atypia, mitotic activity, endothelial proliferation and 
necrosis [5]. In particular, it is possible to distinguish four different classes of astrocytomas: pilocytic 
astrocytoma (grade I), diffuse or fibrillary astrocytoma (grade II), anaplastic astrocytoma (Grade III), and 
glioblastoma multiforme (grade IV). The tumours belonging to the class I and II are considered with low-
grade malignancy, while those of III and IV class are considered to be high-grade malignant [5]. 
Glioblastoma multiforme or simply glioblastoma (GBM) (WHO grade IV) is the most frequent malignant 
primary brain tumour and it is one of the most aggressive cancer. Indeed, GBM is characterized by one of 
the worst survival rates of all the human cancers with a median survival ranging from nine to twelve months 
[1,3]. Patient survival does not improve even after aggressive treatment with multiple approaches, such as 
surgery, chemotherapy and radiotherapy. The surgical approach often cannot be applied without functional 
loss of large areas of central nervous tissue with severe neurological impairment [6]. 
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As defined by the term “multiforme”, GBM comprises morphologically heterogeneous neoplasms, in which 
the cellular composition can be highly variable. GBM is characterized by uncontrolled cell proliferation, 
diffuse infiltration, massive angiogenesis, high genomic instability, strong resistance to apoptosis and then to 
radio-chemotherapy, all distinguishing features representing useful prognostic factors for overall survival [7-
9].  
Two classes of GBM have been identified: primary GBM (or GBM de novo) and secondary GMB [3]. Primary 
GBM accounts for about 90% of GBM cases and it is diagnosed without evidence of a previous lower-grade 
tumour. Primary GBM generally occurs in elderly patients (60-70 years old) and it is characterized by a very 
short clinical history (less than 3 months). On the other hand, secondary GBM, representing the minority of 
GBM cases, derives from a lower-grade tumour that undergoes the process of tumour progression to higher 
malignancy grades. Secondary GBM usually occurs in adults between fifty and sixty years, and the time of 
progression from lower to higher degree of malignancy ranges from months to decades [9,10]. 
 
 
1.2 Altered signalling pathways in glioblastoma tumorigenesis 
Despite glioblastomas are strikingly heterogeneous, common alterations in specific cellular signal 
transduction pathways and cellular functions occur in most malignant gliomas. These alterations include 
pathways involved in the regulation of important cellular processes, such as proliferation, survival, 
differentiation, migration, DNA repair and apoptosis. In particular, the main pathways altered in glioblastomas 
include p53, pRB, growth factors, PI3K/Akt, apoptosis and angiogenesis signalling (Fig. 1) [3,10-13]. 
 
p53 pathway 
The p53 protein is one of the most important tumour suppressors. Its expression is up-regulated in response 
to conditions of cellular stress, such as γ and UV radiation, hypoxia, DNA damage and inappropriate 
oncogene activation. p53 acts as a transcription factor promoting the expression of genes that block the cell 
cycle and genes that repair DNA. If the amount of damage is beyond the cell’s capacity for repair, p53 
favours the expression of genes involved in apoptosis, promoting cell death.  
p53 inactivating mutations are frequent in secondary GBM. Alterations of regulators of p53 levels and/or 
activity are common in primary GBM. For example, Mdm2 protein is a negative regulator of p53: Mdm2 binds 
to p53 promoting its ubiquitination and subsequent degradation via proteasome. Mdm2 is overexpressed in 
some GBM. Furthermore, the p14ARF protein, which negatively regulates the Mdm2 ability to bind p53, is 
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often deleted in malignant gliomas or the corresponding gene is methylated so that its expression is 
inhibited. The abnormal p53 pathway functioning leads to a greater tolerance to DNA damages resulting in 
genomic instability [11,13]. 
 
pRb pathway 
The retinoblastoma protein (pRb) is a tumour suppressor involved in the regulation of the cell cycle, 
controlling cells transition from the G1 into the S phase. Cyclins/cyclin-dependent kinase (Cdk) complexes 
and Cdk inhibitors play a fundamental role in the regulation of cell proliferation. In particular, the cyclin 
D/Cdk4 complex catalyses the pRB phosphorylation resulting in the release of E2F transcription factors 
sequestered by the pRB binding, which are essential for the expression of the S-phase-genes, thus inducing 
DNA synthesis. Moreover, the p16INK4a protein inhibits cell cycle progression, negatively regulating the 
formation of the complex cyclin D/Cdk4. Inactivating mutations of pRB and p16INK4a or the amplification of 
genes coding for Cdk4 and cyclin D are typical features of glioblastomas. All of these changes cause the 
pRB inability to bind E2F, resulting in an uncontrolled cell cycle progression from G1 to S phase [11,13]. 
 
Growth factor signalling 
Different growth factors can inappropriately activate proliferation in most malignant gliomas. The main growth 
factors involved in determining the GBM phenotype are: epidermal growth factor (EGF), platelet-derived 
growth factor (PDGF), insulin-like growth factor-1 (IGF1) and the vascular endothelial growth factor (VEGF). 
Tumours activate the corresponding pathway through the following mechanisms: ligand or receptor over-
expression, receptor mutation causing its constitutive activation in the absence of the ligand, activation of 
intracellular messengers through mutation and/or a change of expression levels and the loss of negative 
regulators. The activated growth factor pathways regulate numerous pro-tumorigenic cell functions able to 
improve proliferation, resistance to apoptosis, motility, invasion, and neo-angiogenesis [9,10]. 
 
PI3K /Akt/PTEN pathway 
Among the pathways altered in glioblastomas there is also the phosphatidylinositol 3-kinase (PI3K)/Akt 
(PKB)/PTEN (Phosphatase and tensin homolog) signalling. PI3K are a family of kinases that phosphorylate 
membrane lipids, in particular phosphoinositides and phosphatidylinositols, such as the phosphatidylinositol 
4,5-bisphosphate (PtdIns (4,5) P2) which is converted in phosphatidylinositol 3,4,5-triphosphate (PtdIns 
(3,4,5) P3). PI3K activation can occur through integrin signalling, receptors with seven transmembrane 
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domains coupled to G proteins or growth factors tyrosine-kinases receptor. The PtdIns (3,4,5) P3 binds to 
different cytosolic proteins, including Akt which undergoes a conformational change that facilitates its 
activation through phosphorylation in correspondence of the two amino acid residues T308 and S473 by 
phosphoinositide-dependent kinases (PDK) 1 and 2, respectively.  
PTEN is a phosphatase that negatively regulates the PI3K/Akt pathway, by converting PtdIns (3,4,5) P3 in 
PtdIns (4,5) P2, thus directly antagonizing PI3K activity. Akt is a key regulator of cell proliferation and survival 
pathways. It is a Serine/Threonine kinases able to inhibit apoptosis, promote cell proliferation and regulate 
lipids and glucose metabolisms, cell movements and vesicle trafficking.  
High levels of phosphorylated/activated Akt and deletions or mutations in the PTEN gene are the most 
common alterations of the PI3K/Akt signalling in glioblastomas. These changes are crucial in determining the 
GBM malignant features, such as rapid tumour growth, invasiveness, resistance to cytotoxic treatments and 
massive angiogenesis [3,12,14]. 
 
Apoptosis 
A hallmark feature of malignant glioma cells is an intense resistance to death-inducing stimuli such as 
radiotherapy and chemotherapy. This biological property has been linked to genetic alterations of key 
regulatory molecules involved in mitogenic signalling, most prominently growth factors and the 
PI3K/Akt/PTEN signalling axis, as well as regulatory and effector molecules residing in classical cell death 
networks of both extrinsic (death receptor-mediated) and intrinsic (mitochondria-dependent) apoptosis 
signalling pathways [15,16].  
The “death receptors” are cell surface molecules that, upon binding their ligands, recruit adapter molecules 
to provide a molecular scaffold for the autoproteolytic processing and activation of caspases. The most 
important death receptor systems include TNFR1, TRAILR1-2 and CD95. These death receptors are often 
down-regulated and their ligand mutated in glioma pathogenesis [12].  
The role of the anti-apoptotic Bcl-2 family members (Bcl-2, Bcl-XL, MCL-1, CED-9) in gliomagenesis has also 
been extensively studied. These proteins modulate apoptosis signalling by preserving mitochondrial 
membrane integrity and the release of cytochrome c, thus blocking the caspase cascade and the apoptotic 
program. These anti-apoptotic Bcl-2 family members are often up-regulated by overexpression in 
glioblastomas [12].  
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Angiogenesis 
GBMs are among the most highly vascular of all solid tumours. Microvascular hyperplasia, the defining 
histopathological phenotype of both primary and secondary GBM, consists of proliferating endothelial cells 
that emerge from normal parent microvessels accompanied by stromal elements, including pericytes and 
basal lamina. Angiogenesis is vital for macroscopic solid tumour growth and one common feature in the 
transition from low-grade to secondary GBM is a dramatic increase in microvascular proliferation. In 
particular, in glioma pathogenesis frequent alterations of different genetic programs converging on a final 
common angiogenesis, include positive (VEGF, PDGF, bFGF, IL-8, SDF-1) and negative (thrombospondin1, 
thrombospondin2, endostatin, tumstatin, interferons) regulators of this process [12].  
 
 
 
 
Figure 1. Altered signalling pathways in glioblastoma tumorigenesis (modified image from Furnari et al. [12]). 
The relationships between survival, pathobiology and the molecular lesions that lead to the formation of primary (de 
novo) and secondary (progressive) glioblastomas are shown. OE, overexpressed; amp, amplified; mut, mutated. 
 12 
1.3 Glioblastoma treatment  
Glioblastomas are among the most devastating tumours and most difficult cancers to treat. GBM grow very 
quickly and show a high resistance to apoptosis, thus to radio-chemotherapy [1,3]. Furthermore, brain 
tumour therapy is even more complex for drug distribution within the intracranial space, due to the presence 
of the blood-brain barrier. The standard therapy for malignant gliomas involves surgical resection when 
feasible, radiotherapy, and chemotherapy. However, very poor prognosis is still associated with GBM, being 
the median survival of patients approximately 1 year [1]. 
Malignant gliomas cannot be completely eliminated surgically because of their infiltrative nature, but patients 
should undergo maximal surgical resection whenever possible. Surgical debulking reduces the symptoms 
from mass effect and provides tissue for histological diagnosis and molecular studies. Advances such as 
MRI (magnetic resonance imaging)-guided neuronavigation, intraoperative MRI, functional MRI, 
intraoperative mapping [17] and fluorescence-guided surgery [18] have improved the safety of surgery and 
increased the extent of resection that can be achieved.  
Radiotherapy is the mainstay of treatment for malignant gliomas. The addition of radiotherapy to surgery 
increases survival among patients with glioblastomas from a range of 3 to 4 months to a range of 7 to 12 
months [19]. It has been reported that chemotherapeutic agents may enhance the effectiveness of 
radiotherapy, resulting in a modest increase in survival (a 6 to 10% increase in the 1-year survival rate) 
[20,21]. In the last years, Stupp and colleagues demonstrated that the combination of radiotherapy and 
temozolomide (TMZ), an oral alkylating agent with good penetration of the blood–brain barrier, followed by 
adjuvant temozolomide therapy, had an acceptable side-effect profile and, as compared with radiotherapy 
alone, increased the median survival (14.6 months vs 12.1 months, p<0.001) [22]. In addition, the survival 
rate at 2 years among the patients who received radiotherapy and temozolomide was significantly greater 
than the rate among the patients who received radiotherapy alone (26.5% vs 10.4%), establishing 
radiotherapy with concomitant and adjuvant temozolomide as a useful combination for newly diagnosed 
glioblastomas. 
 
 
 13 
1.4 Temozolomide in glioblastoma treatment  
As described above, in recent years TMZ has become the current mainstay of anti-glioblastoma therapy, 
ameliorating patient prognosis. TMZ is also used in clinical treatment of metastatic melanoma and has 
shown promising effects in refractory acute leukemia [23-25]. TMZ is an alkylating agent fully active when 
administrated orally (100% bioavailability). This compound has excellent pharmacokinetic properties and it is 
able to cross the blood brain barrier due to its lipophilic character, causing minimal side effects [26-28]. 
TMZ is an imidazotetrazin and, after intestinal adsorption, at physiologic pH and without hepatic activation, it 
is spontaneously hydrolyzed to its active metabolite MTIC (methyl-triazen-imidazole-carboxamide). MTIC is 
an unstable compound, which undergoes degradation with the generation of the inactive 5-aminoimidazole-
4-carboxamide (AIC), which spontaneously produces molecular nitrogen, and the eletrophilic 
methyldiazonium cation. The methyl-diazonium is a highly reactive molecule acting as an alkylating agent, 
resulting in the methyl group transfer on the DNA (Fig. 2) [29]. In particular alkylating agents are able to 
methylate nucleophilic sites (mainly groups containing nitrogen, oxygen and sulphur) of cellular 
macromolecules. These agents could potentially damage all cellular macromolecules; however, their 
biological effects, i.e. cytotoxicity and mutagenicity, are due to their ability to damage DNA. The alkylating 
agents bind covalently to DNA nucleophilic residues, establishing intermolecular and intramolecular cross-
linking. The oxygen and nitrogen atoms present in the DNA bases are the main target of alkylation. The main 
damaged DNA sites are the N7 or O6 positions of guanine residues (accounting for nearly 70% and 7% of the 
methylated lesions, respectively) and N3 position of adenine residues (10% of lesions). However, although it 
is the minor product of alkylation, the methylation of the O6 position of guanine is considered the major 
mediator of temozolomide toxicity. Guanine alkylation leads to changes in the DNA structure and functions: 
- alteration of the genetic code, because the structure of the alkylated guanine favours the formation of a 
base pair with the abnormal insertion of a thymidine instead of a cytosine during subsequent DNA 
replication (base/base mismatches); 
- cleavage of the guanine imidazole ring; 
- loss of a guanine residue and consequent breaking of the DNA helix [30]. 
Summarizing, the therapeutic benefit of temozolomide depends on its ability to alkylate/methylate DNA. This 
methylation damages the DNA and triggers tumour cells death. 
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Figure 2. Activation and mechanism of action of TMZ [30]. 
 
 
Although the mechanism of cell death induced by the therapeutic treatment with TMZ is not yet entirely clear, 
extensive evidence shows that this drug induces the processes of apoptosis or autophagy.  
Sur and co-workers [31] demonstrated that TMZ is able to induce apoptosis in T98G cells from human 
glioma. This evidence has been confirmed through morphological techniques (TUNEL assay) which 
demonstrated the presence of nuclear DNA fragmentation after TMZ treatment. Apoptosis induction occurs 
through the intrinsic activation pathway with the down-regulation of the pro-apoptotic Bax levels and the up-
regulation of the anti-apoptotic Bcl-2, these events are related to the activation of cysteine proteases such as 
calpain and caspase-3. 
On the other hand, Kanazawa and colleagues [32] demonstrated that the treatment of T98G human glioma 
cell line with TMZ induces the activation of the autophagy process. This evidence has been demonstrated by 
a morphological assay based on the use of acridine orange which allows detecting the formation of acidic 
vesicular organelles, typical of the autophagy process. Moreover, a biochemical analysis showed an 
increased expression of the LC3 protein (microtubule-associated protein 1-ligth chain 3), marker of the 
autophagic process, after TMZ treatment. 
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1.5 Temozolomide resistance 
Despite the introduction of the alkylating agent temozolomide in glioblastoma therapy has improved patient 
survival, drug resistance mechanisms limit its benefits and the prognosis remains unfavorable [33]. The 
biological effects of TMZ and cell resistance to them depend on at least three DNA repair systems, (a) O6-
alkylguanine-DNA-alkyltransferase, called also methyl-guanine methyl-transferase (MGMT); (b) mismatch 
repair (MMR) and (c) base excision repair (BER) (Fig. 3) [34,35]. 
 
One of the best characterized mechanisms of TMZ resistance is the protein MGMT. MGMT is a small 
enzyme-like protein that removes small alkyl adducts from the O6 position of the DNA guanine through a 
stoichiometric and auto-inactivating reaction. This reaction consists in a covalent transfer of the alkyl group 
from the alkylated sites in DNA to a conserved cysteine residue (Cys 145) within the active site of the MGMT 
protein. This transfer causes the irreversible inactivation of MGMT which is subsequently ubiquitinated and 
undergoes degradation via proteasome. This is the reason why MGMT is considered a “suicide enzyme“ 
[30]. MGMT is ubiquitously expressed in normal human tissues and its expression is often higher in 
malignant tissues that in the normal counterpart. MGMT appears to be overexpressed in malignant gliomas 
and represents the major obstacle in the treatment of these cancers, because it repairs the DNA damages 
caused by TMZ, resulting in poor patient survival [36]. MGMT expression can be induced by glucocorticoids, 
cyclic AMP, and protein kinase C (PKC) activators. Furthermore, MGMT expression is also regulated by the 
methylation status of specific CpG regions of its gene-promoter. Hypermethylation of these MGMT promoter 
regions (found in about 45% of gliomas) silences the gene, resulting in loss of expression and is strongly 
associated with prolonged survival in malignant glioma patients treated with temozolomide [37]. 
Since high levels of MGMT are responsible for resistance to TMZ, its inhibition represents a possible target 
to improve drug sensitivity. In fact, it has been demonstrated that the treatment with MGMT inhibitors - i.e. 
O6-benzylguanine or O6-(4-bromotenyl)guanine (Lomeguatrib) - sensitizes human glioma cells to TMZ 
treatment. This evidence suggests that a therapy combination with temozolomide and MGMT inhibitors may 
be an effective tool to treat resistant gliomas [38]. 
MMR is represented by a protein complex dedicated to the repair of biosynthetic errors generated during 
DNA replication. The MMR system recognizes base mismatches and insertion-deletion loops, cuts the 
nucleotide sequence containing the lesion, and restores the correct base sequence. Therefore, not only 
MGMT but also MMR is involved in target cell susceptibility to TMZ.  
However, the MMR system does not suppress, but instead promotes the cytotoxic effects of TMZ. In fact, 
MMR is not able to repair the incorrect base pairing determined by treatment with TMZ, failing to find a 
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complementary base for the methylated guanine. According to a predominant hypothesis, this event causes 
reiterated "futile" attempts of damage repair, with the generation of long-lived nicks in the DNA, leading to the 
activation of cell cycle arrest and apoptosis [30,39]. A deficiency in the MMR pathway, resulting from 
mutations in any one or more of the proteins forming the complex repairing DNA, has been observed in 
malignant gliomas. This deficiency lead to tolerance of TMZ-generated DNA adducts, a continuation of DNA 
replication, and a loss of the cytotoxic effects of temozolomide [40,41]. 
BER removes DNA lesions due to physical or chemical agents. In particular, BER is able to repair N7-
methylguanine and N3-methyladenine determined by treatment with alkylating agents, such as TMZ. Recent 
attempts to overcome resistance to temozolomide conferred by mismatch repair deficiency have focused on 
blocking base excision repair. One of the strategies used to block base excision repair includes the inhibition 
of a key enzyme, the poly(ADP-ribose) polymerase 1, PARP1 [42], which binds to and is activated by DNA 
strand breaks, is thought to be important in protecting and trimming the DNA ends for repair synthesis [43]. 
In presence of PARP1 inhibitors, the repair process of N-methylpurines cannot be completed and the 
deriving DNA strand breaks contribute to cytotoxicity. Several studies demonstrated that the inhibition of 
PARP1 increases the efficacy of temozolomide in the treatment of malignant glioma cells and this effect was 
especially evident in tumours deficient in DNA mismatch repair, since cancer cells are tolerant to O6-
methylguanine damage and show low sensitivity to TMZ [44,45]. These studies indicate a role of the repair of 
N-methylpurine adducts in the resistance to the antitumour activity of temozolomide and other alkylating 
agents. Thus, a pharmacological strategy based on the interruption of N-methylpurine repair might represent 
a novel strategy to restore or increase glioma sensitivity to TMZ. 
 
 
 
Figure 3. Summary of TMZ resistance mechanisms (modified image from Zhang et al. [35]). 
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1.6 Glioblastoma stem cells 
For more than a century, human cancers have been recognized as a morphologically heterogeneous 
population of cells. What has become clear in the past 10 years is that these cells are also functionally 
heterogeneous [46]. Recent studies suggest the existence of a subpopulation of cells within the tumour mass 
(about 3-5% of the total cancer cell population), named cancer stem cells (CSCs) which play a crucial role in 
both the initiation and maintenance of cancer, and might play an important role in its malignant behaviour. 
This model of cancer growth is called hierarchical model (or cancer stem cell hypothesis). This postulate 
implies that the bulk of cancer cells within a tumour are progeny of CSCs, have no tumorigenic potential, 
thus cannot regenerate new tumours, and might represent a mix of partially differentiated cancer progenitor-
like cells with limited proliferative capacity, terminally differentiated, an death committed cancer cells [46].  
CSCs have now been identified and isolated in different tumours: haematopoietic, breast, prostate, colon, 
head and neck and pancreas cancers [46]. Moreover, the presence of cancer stem cells has been recently 
demonstrated in central nervous system tumours, particularly in GBM [47-51].  
Glioblastoma stem cells (GSCs), similarly to the normal neural stem cell counterpart (NSCs), are able to self-
renew, thus able to go through numerous cycles of cell division while maintaining their undifferentiated state. 
Moreover, GSCs emerged as multipotent, thus able to simultaneously differentiate into multiple lineages 
(neuron, astrocytes and oligodendrocytes). More importantly, these cells were described as tumour-founding 
cells, able to regenerate a phenocopy of the original GBM when injected in immunocompromised mice. 
Notably, GSCs are also highly resistant to chemo-radiotherapy [50-53]. These characteristics suggest that, 
despite GSCs represent a minority component of the tumour mass, they are critical in determining the GBM 
initiation, progression and malignancy. 
Another peculiarity of GSCs is the increased expression of the main brain cancer stem cell markers: the 
cytoskeleton protein nestin and the membrane glycoprotein CD133 [54-56]. Nestin is an intermediate 
filament (IF) protein expressed in the stem/progenitor proliferating cells during the central nervous system 
developmental stages and its expression is down-regulated in differentiated cells. It may be involved in the 
organization of the cytoskeleton, cell signalling and metabolism, organogenesis, and represents the 
proliferation, migration and multi-differentiated characteristics of multi-lineage progenitor cells [56]. CD133 
(also named as Prominin) is a membrane glycoprotein expressed in normal human neural stem cells, and it 
is down-regulated in differentiated cells. Five alternative promoters, three of which are partially regulated by 
methylation, drive the transcription of several mRNA isoforms of CD133. Its localization is in membrane 
protrusions, which suggests an involvement in the mechanisms influencing cell polarity, migration and 
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interaction of stem cells with neighbouring cells and/or extracellular matrix [54]. Nestin and CD133 
expression may be a potential indicator of the biological aggressiveness of gliomas. These 2 proteins can be 
considered as markers of tumour burden, and recurrence in human gliomas [55]. 
However these molecules are not the universal enriched markers for GSCs. Indeed it has been observed 
that the stage-specific embryonic antigen CD15 could be also a good candidate to isolate GSCs. CD15+ 
cells are often also CD133+ and, within the tumour, are able to self-renewal, show a multilineage 
differentiation potential and are highly tumorigenic in vivo [57]. 
The GSC origin remains a subject of ongoing debate in the actual scientific literature. Current hypothesis 
postulate that GSCs either originate from transformed neural stem cells or neural progenitor in the brain or 
that they de-differentiate from mature brain mutant cells and reacquire phenotypic and functional 
characteristics of neural stem cells (Fig. 4) [52,56].  
 
 
 
 
Figure 4. GSC origin (modified image from Singh et al. [47]). 
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1.7 Altered molecular pathways in glioblastoma stem cells 
The GSC component differs from normal neural stem cells for a complete de-regulation of the major signal 
transduction pathways involved in fundamental cellular processes such as cell proliferation, differentiation, 
stemness maintenance, as well as drug- and radio- resistance [58]. The main pathways altered in GSCs 
include Notch, Hedgehog-GLIs, growth factors, BMP, and TGF-β signalling (Fig. 5). 
 
Notch pathway 
Notch proteins are a family of single transmembrane domain receptors involved in cell-cell communication. 
Upon binding with one of its ligands (Jagged 1-2, Delta like 1-3-4), Notch is cleaved by the γ-secretase 
complex. The Notch intracellular domain is thus released from the plasma membrane, and translocates into 
the nucleus where it acts as a transcription factor. In the nervous system, Notch is able to induce 
proliferation and self-renewal of neural stem cells while suppressing their differentiation. Alterations of Notch 
signalling are frequent in GSCs. In particular, Notch overexpression and its ligand-independent activation 
were observed. The de-regulation of this signalling pathway causes an increased GSC growth and 
proliferation [59,60]. 
 
Hedgehog pathway 
The binding of the Hedgehog ligands to their receptors activates transducers termed GLIs (named for their 
discovery in gliomas), which then translocate into the nucleus to activate or repress downstream targets. The 
Hedgehog pathway is one of the key regulators of embryogenesis and is critical for the survival of several 
different types of normal stem cells, including neural stem cells [61]. Hedgehog signalling is also active in 
gliomas and contributes to GSCs function, favouring cell proliferation, self-renewal, tumorigenicity and drug 
resistance [62]. Furthermore, it has been demonstrated that Hedgehog pharmacologic inhibitors (i.e. 
cyclopamine) improve traditional therapy efficiency against gliomas. In particular, Bar and colleagues 
demonstrated that cyclopamine treatment improves the effects of radiation on GSC survival [63]. 
 
Growth factors signalling 
GSCs are also characterized by the deregulation of growth factor signalling (EGF, bFGF, PDGF and IGF). 
GSCs activate these pathways through different mechanisms, such as ligand and/or receptor 
overexpression, receptor mutation causing its constitutive activation, intracellular messenger activation 
through mutation or the loss of expression of negative regulators [59]. 
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The signal initiated by the binding between growth factors and their receptors (Receptor Tyrosine Kinases, 
RTKs) is transduced and amplified through downstream molecule cascades, such as the pro-survival 
AKT/PI3K pathway. Upon activation, AKT promotes survival, proliferation, invasion, and secretion of pro-
angiogenic factors. It has been recently demonstrated that GSCs are more dependent on AKT signals than 
matched non-stem glioma cells. Pharmacologic inhibitors of AKT attenuate the generation of neurospheres, 
the structures usually formed by GSCs in culture, suggesting that AKT inhibition may specifically target the 
GSC population to reduce tumour malignancy [64]. 
 
BMP pathway 
Bone Morphogenic Proteins (BMPs) are a family of growth factors named for their central roles in bone and 
cartilage formation. Most BMPs elicit their actions through binding to cell-surface receptor kinases (the 
BMPRs). This binding activates, through phosphorylation, Smad1/5/8 proteins that bind to the co-activator 
Smad4, translocate into the nucleus, and regulate transcription. BMPs are crucial factors that regulate 
proliferation and apoptosis in neural stem cells and usually promote the differentiation of these cells [58]. Lee 
and collaborators demonstrated that this pathway is altered in GSCs. In particular, in GSCs the BMP 
receptor expression is regulated by epigenetic alterations leading to a reduced expression and signal 
transduction. In this way GSCs are able to escape the differentiation process induced by BMPs, thus 
keeping intact their stemness [65].  
 
TGF-β pathway 
The TGF-β superfamily includes a large number of proteins capable of regulating crucial cellular processes 
such as differentiation and cellular development [59]. Recent experimental evidence demonstrated that 
GSCs are able to produce and release TGF-β into the extracellular microenvironment, which acts in an 
autocrine/paracrine way inducing cell survival and stemness maintenance through the activation of Sox2 
signal transduction pathway [66]. 
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Figure 5. Complex signalling pathways and cellular factors regulate GSCs [58]. 
 
 
Transcription factors, epigenetic regulators, and miRNAs are extremely powerful regulators of normal and 
cancer cells. They are capable of simultaneous regulation of multiple downstream targets and are implicated 
also in the maintenance of GSC properties. Many evidence shows that the main factors involved are: Sox2, 
Oct4, Nanog, Olig 2, c-Myc and Bmi1 [58]. 
 
Sox2-Oct4-Nanog 
Sox2, Oct4 and Nanog are transcription factors crucial for the regulation of the balance between self-renewal 
and differentiation in embryonic and adult stem cells [59]. Oct4 is highly expressed in many human glioma 
specimens and cell lines, and its expression correlates with the glioma grade [67]. The direct role of Oct4, 
Sox2 and Nanog in glioma CSCs is not well understood, but overexpression of Oct4 in rat C6 glioma cells 
increases the expression level of the stemness marker Nestin. These data suggest that Oct4 may inhibit the 
differentiation of glioma CSCs and contribute to CSC stemness maintenance [67]. 
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Olig2 
Olig2 is a transcription factor that is almost exclusively expressed in the central nervous system. During brain 
development, Olig2 is expressed in neural progenitor cells that give rise to oligodendrocytes and certain 
neuronal subtypes [58]. Functionally, Olig2 is expressed in both normal neural stem cells and glioma CSCs. 
Olig2 sustains the replication-competent state of neural progenitors and is necessary for the multilineage 
differentiation potential of neural progenitors. In GSCs Olig2 regulates the process of cell proliferation and 
inhibits the differentiation process through the suppression of the cell cycle regulatory protein p21WAF1/CIP1 
[68]. 
 
c-Myc 
c-Myc is a transcription factor, considered as an oncoprotein, extensively studied for its instrumental role in 
the proliferation of both normal stem cells and tumour cells. It has been recently demonstrated that glioma 
CSCs express high levels of c-Myc and that c-Myc is required both for maintenance of GSCs in vitro and for 
their tumorigenic capacity in vivo [69]. It has been demonstrated that c-Myc additionally prevents 
differentiation and promotes self-renewal of GSCs derived from a p53/PTEN double knock-out mouse model 
[70]. 
 
BMI1 
BMI1 belongs to the Polycomb group genes, which usually function as epigenetic silencers. BMI1 has been 
implicated in determining stem cell fate in multiple tissues and is a positive regulator of neural stem cell self-
renewal. BMI1 is also a known oncogene frequently overexpressed in many cancer types, including gliomas 
[58]. As demonstrated by Abdouh and colleagues, BMI1 is overexpressed also in GSCs and is required to 
sustain the self-renewal process of these cells [71]. 
 
miRNAs 
miRNAs are small noncoding RNAs that can silence target genes through post-transcriptional mechanisms 
on target mRNAs. miRNAs are powerful intracellular regulators because a single miRNA can regulate many 
distinct mRNAs. In cancer biology, miRNAs can function as oncogenes or as tumour suppressors.  
Two recent reports directly investigated the roles of miRNAs in glioma CSCs. The levels of miR-124 and 
miR-137 are reduced in grade III and IV malignant gliomas in comparison with normal brain. Overexpression 
of these two miRNAs inhibits proliferation while inducing differentiation of glioma CSCs, indicating a tumour 
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suppressor role for these two miRNAs in GSCs [72]. Similarly, another miRNA, miR-451, is expressed at 
lower levels in CD133+ GSCs in comparison with CD133− non-stem glioma cells. In particular, it has been 
demonstrated that miR-451 inhibits the growth of glioma CSCs and disrupts the formation neurosphere, the 
structures usually formed by GSCs in culture [73].  
 
 
1.8 Glioblastoma stem cells in tumour pathogenesis 
Despite advances in treatment strategies that combine surgery with radiotherapy and chemotherapy, GBM 
remains one of the most deadly disease with a high rate of recurrence after treatment. Growing evidence 
suggests that GSCs play a crucial role in the GBM malignant behaviour, being involved in the processes of 
radio and chemo-resistance, recurrence, metastasis and angiogenesis [53,56,74]. 
Radiotherapy is one of the most important therapeutic approaches in GBM treatment, but in most cases it 
becomes a simple palliative treatment due to the presence of a population of radio-resistant tumour cells. 
Gliomas usually respond to radiation treatment, but subsequently radiation resistant cells recur. GSCs 
appear to contribute to the onset of radio-resistance. In fact, Bao and colleagues demonstrated that GSCs, in 
response to DNA damage induced by ionizing radiation or by radio mimic drugs, rapidly activate the 
response to DNA damage by phosphorylation of proteins fundamental in this mechanism such as ATM, 
Rad17, Chk1 and Chk2. The activation of these proteins allows the arrest of the cell cycle and a rapid repair 
of the DNA damage, thus favouring cell survival and consequently the onset of radio resistance. In particular, 
CD133-expressing tumour cells preferentially activate the DNA damage check points in response to 
radiation, and repair radiation-induced DNA damage more effectively than CD133-negative tumour cells [75]. 
Chalmers proposed that up-regulated and hyper-responsive cell cycle checkpoint pathways in GSCs may be 
a potential target for therapy [76]. 
A novel approach for GBM treatment is the pharmacological treatment by the administration of the alkylating 
agent TMZ concurrently during radiotherapy, followed by adjuvant TMZ therapy. As described above, this 
drug has a cytotoxic effect on tumour cells, as it induces the methylation of guanine at the O6 position, 
causing the formation of DNA adducts favouring the cell cycle arrest and the activation of the cell death 
process. 
It has been demonstrated that GSCs are resistant to cytotoxic drugs. This intrinsic property is frequently 
related to the high expression levels of the DNA repair protein MGMT, which is capable of removing the 
methyl groups added to the DNA by alkylating agents. This characteristic makes GSCs insensitive to 
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pharmacological treatment, thus increasing the tumour survival [77]. Growing evidence suggests that also 
active drug extrusion mechanisms could play a crucial role in drug resistance observed in GSCs. In 
particular, it has been demonstrated that GSCs are characterized by an increased expression of the ABCG2 
transporter, member of the ABC transporter family [77,78]. Also ABCB1 (or PgP), and multi-drug resistance 
proteins 3 (MDR-3) were found overexpressed in GSCs [74]. The high expression of these proteins able to 
transport outside the cells anticancer drugs such as Temozolomide, Etoposide, Paclitaxel and Carboplatin, is 
related to the ability of these cells to escape the pharmacological treatment with the onset of drug resistance. 
Moreover, also alteration in the apoptotic and autophagic machinery could contribute to GSC 
chemoresistance. The down-regulation of the main autophagy-related proteins, such as Beclin1, ATG5 and 
LC3-II has been observed in GSCs. The expression levels of these proteins are low, even after TMZ 
treatment [79]. GSCs are also characterized by an overexpression of apoptosis suppressor such as Bcl2, 
Bcl-XL, FLIP and several inhibitors of apoptosis, such as IAPs proteins which bind and inhibit caspases 3-7-
9, preventing apoptosis [77,80]. 
Malignant gliomas are characterized by florid angiogenesis, with neovascularization significantly correlated 
with enhanced tumour aggressiveness, degree of tumour malignancy, and poor clinical prognosis. Indeed, 
active angiogenesis plays a key role in providing oxygen and nutrients to the tumour mass as well as 
facilitating metastasis. Given the importance of CSCs in glioma maintenance, it is not surprising that GSCs 
and angiogenesis are tightly connected. Bao and colleagues demonstrated that, in comparison with matched 
non-stem cancer cells, GSCs have a stronger capacity for promoting angiogenesis, partially through 
amplified secretion of VEGF, one of the most important pro-angiogenic factors [81].Treating GSCs with the 
VEGF-neutralizing antibody Bevacizumab attenuates their ability to promote angiogenesis both in vitro and 
in vivo. The mechanism underlying the specific up-regulation of VEGF in GSCs is still unclear, but it has 
been suggested that environmental factors such as hypoxia and acidosis play important roles in this process 
[58].  
Notwithstanding, the precise mechanisms underlying the chemoresistance and the malignancy of GSCs are 
not completely understood. Thus, the molecular characterization of GSCs represents a critical step in 
defining glioblastoma properties, and may be essential in developing effective therapeutic strategies for the 
complete eradication of the tumour. 
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2. SPHINGOLIPIDS 
 
Sphingolipids are essential constituents of eukaryotic cell membranes. For long time they have been 
considered merely as structural components, fundamental in the definition of the membrane bilayers. In the 
last 20 years advances in biochemical and molecular research led to the identification of sphingolipids acting 
as intra- and extra-cellular messengers involved in the regulation of crucial aspects of cell biology such as 
cell growth, death, migration, senescence and inflammatory response [82].  
Sphingolipids are amphipathic molecules, characterized by a hydrophilic (or polar head) and a hydrophobic 
(or tail) portion. The structural element common to all sphingolipids is represented by ceramide (Cer). It 
consists of a long-chain sphingoid base, linked via amide bond to a long-chain fatty acid, predominantly 
palmitic (C16) or stearic acid (C18) (Fig. 6). Sphingosine (Sph), an amino-alcohol containing 18-20 carbon 
atoms (C-18 or C-20) and characterized by the presence of a double bond across C4-C5, is the most 
frequent sphingoid base constituting Cer in humans, followed, in very small proportions, by C-18/C-20 
sphinganine (which lacks the double bond C4-C5). Both are in the trans D-erythro form. 
Cer is the central building block of all sphingolipids, and represents the hydrophobic portion, or tail, of these 
molecules. Through its primary alcoholic residue, Cer can be conjugated to different hydrophilic groups, 
which represent the polar head of sphingolipids. Cer binding to phosphocholine or saccharidic structures 
leads to the generation of sphingomyelins (SM) and glycosphingolipids (GSLs), respectively. The 
oligosaccharide portion of sphingolipids may contain 15-20 saccharidic units, among which, the most 
frequent are glucose, galactose, N-acetylglucosamine, N-acetylgalactosamine and different species of sialic 
acid, linked to Cer through a β-glycosidic bond. Furthermore, both the sphingoid base (sphingosine) and Cer 
may exist in the phosphorylated form in correspondence with the carbon in position 1 (C-1), thus the primary 
alcoholic residue is functionalized [83]. 
 
 
 
 
Figure 6. Ceramide chemical structure [84]. 
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Sphingolipids are ubiquitous membrane components, being present in different organelle membranes and 
particularly abundant in the plasma membrane. Cer is present in small amounts within cell membranes, as it 
functions primarily as an intermediate of complex sphingolipid metabolism and acts as a cell signalling 
mediator [85]. In biological plasma membranes, SM and GSLs represent the major sphingolipids, displaying 
an asymmetric or polarized distribution, and play important roles in the regulation of membrane fluidity and 
sub-domain structures. In particular, GSLs are mainly localized in the outer leaflet of the cell membrane. 
Their saccharidic portion is exposed on the cell surface, while the hydrophobic portion, constituted by Cer, is 
inserted within the outer leaflet of the membrane. Glycosphingolipids show a distribution on the membrane 
specific for each cell type, which can vary with differentiation and neoplastic transformation [84]. 
Sphingolipids, thanks to their amphipathic properties, are able to diffuse laterally within the membrane and, 
together with cholesterol and specific proteins, may give rise to microdomains, specialized platforms able to 
compartmentalize cellular processes by serving as organizing centres for the assembly of signalling 
molecules [86].  
 
 
2.1 Sphingolipid metabolism 
Sphingolipids can originate from both the "de novo synthesis" or from the degradation of complex 
sphingolipids (Fig. 7) [87]. 
The "de novo" biosynthesis of sphingolipids begins with the condensation of palmitoyl-CoA with L-serine. 
This reaction is catalyzed by the enzyme serine-palmitoyl transferase (SPT) and leads to the formation of 3-
ketosphinganine, which is subsequently reduced to sphinganine by a NADPH-dependent oxidoreductase, 
the 3- ketosphinganine reductase. Sphinganine is the substrate of the (dihydro)-Cer synthase (CerS), which 
uses an acyl donor (often palmitoyl-CoA, but also stearoyl-CoA) to bind sphinganine to a fatty acid, forming 
dihydroCer. In mammalian cells six different isoforms of CerS have been recently identified and are encoded 
by six different genes, members of the LASS family (Longevity Assurance Genes). Each of these genes 
specifically synthesise one of the several Cer species which differ in the fatty acid chain length. In particular, 
LASS1 is involved in the production of C18Cer, LASS2 of C22Cer, LASS3 of C18/C24Cer, LASS4 of C20Cer, 
LASS5 and LASS6 of C16Cer and C14/C16Cer respectively [88,89]. The product of the reaction catalyzed by 
CerS, dihydroCer, is desaturated in position 4,5 of the sphingoid base by a NADPH-dependent 
oxydoreductase, the dihydroCer desaturase (DES), with the consequent formation of Cer [90]. All the 
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enzymes involved in the de novo biosynthesis of Cer are localized in the endoplasmic reticulum (ER) 
membrane, acting on the cytosolic surface of the same, and the reaction products remain there anchored. 
Cer is the common precursor for the synthesis of all complex sphingolipids. Through its hydroxyl group of the 
carbon in position 1, Cer can bind to additional functional groups, generating glycosphingolipids (GSL), Cer 
1-phosphate and sphingomyelin (SM).  
Glycosphingolipids derive from the conjugation of the Cer primary alcoholic residue with one or more 
saccharide units, through β-glycosidic bond.  
Galactosylceramide (GalCer) is synthesized from Cer and UDP-galactose by the galactosyltransferase, 
enzyme expressed at the luminal side of the ER membrane in Schwann cells and oligodendrocytes. GalCer 
is an important lipidic component of myelin (formed by Schwann cells in the PNS and oligodendrocytes in the 
CNS), and confers rigidity and stability to the membranes, allowing a correct conduction of nerve impulses 
[91]. 
Glucosylceramide (GlcCer) is obtained from Cer and UDP-glucose, through a reaction catalyzed by GlcCer 
synthase (GCS), enzyme localized at the cytosolic leaflet of the Golgi apparatus [92]. So, GlcCer 
biosynthesis requires an efficient transport mechanism of Cer from the cytoplasmic side of the RE to the 
cytoplasmic side of the cis-Golgi. Once synthesized, GlcCer can be routed directly to the plasma membrane 
(via a vesicular system), or it can be further modified by subsequent glycosylations, with the consequent 
production of more complex glycosphingolipids, such as gangliosides. This process is catalyzed by different 
glycosyl-transferases acting by associating to GlcCer individual saccharide units, following a precise 
sequential order. The enzymes involved in these reactions are located and act in the luminal surface of the 
Golgi cisternae; a flippase enzyme mediating the translocation of GlcCer from the cytoplasmic to the luminal 
side of the cis-Golgi, so that subsequent glycosylations can take place [93,94]. 
Cer can also undergo phosphorylation of the hydroxyl group of the carbon in position 1 by the Cer kinase 
(CK), with the consequent formation of Cer 1-phosphate (Cer1P) [82]. The subcellular localization of this 
enzyme has not been definitely identified, but it seems to be at the level of the plasma membrane, the Golgi 
apparatus, and the cytoplasm [95].  
SM represents approximately 10% of the lipids present in mammalian cells. SM synthesis is based on the 
transfer of phosphocholine from phosphatidylcholine to Cer, with the production of a diacylglycerol (DAG) 
molecule. This reaction is catalyzed by SM synthase (SMS). Several studies suggest the existence of 2 
different enzymatic SMS isoforms: SMS1, localized in the luminal side of the cis/medial Golgi apparatus and 
SMS2, primarily localized to the plasma membrane [82,96]. Experimental evidence has shown that about 
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90% of the de novo synthesis of SM occurs in the cis/medial Golgi, and only a small percentage occurs at 
the level of the plasma membrane. So most of SM biosynthesis, as well as that of GlcCer, requires a 
mechanism of Cer transport from the RE, where it is synthesized, to the Golgi apparatus. The localization of 
SMS2 at the plasma membrane suggests its role as a regulator of SM and Cer levels for signalling pathways 
and signal transduction. 
Sphingolipids reach their final destination at the plasma membrane mainly following the vesicular flow of 
exocytosis from the ER or the Golgi apparatus to the plasma membrane. 
Membrane glycosphingolipids are constitutively degraded by a process involving endocytosis and the endo-
lysosomal district; the enzymatic steps of this degradation process include exoglycohydrolases requiring an 
acidic pH, guaranteed within the lysosomal or endosomal vesicles, in order to perform their catalytic activity. 
These enzymes catalyze the glycosphingolipids degradation in monosaccharides and Cer components, 
determining the sequential hydrolytic detachment of monosaccharides [97]. 
SM degradation is catalyzed by sphingomyelinase (SMase), an enzyme able to hydrolyze the SM 
phosphodiester bond, with the consequent formation of Cer and phosphocholine. Three isoforms of this 
enzyme have been described and distinguished, according to their subcellular localization and the optimum 
pH, in acidic, neutral, and alkaline SMase. The acid SMase is located mainly in the lysosomal compartment. 
Another isoform of acidic SMase has been identified, due to a splice variant in the transcription of the 
encoding gene; this enzyme can be secreted or localized in the outer membrane leaflet [82,98]. The neutral 
SMase has various subcellular locations including the inner leaflet of the plasma membrane, ER, Golgi, and 
even the nucleus [98]. The localization of alkaline SMase is more restricted, being mainly expressed in the 
intestinal tract, and in the bile where it participates to SM digestion [99].  
Cer is degraded by ceramidases (CDases); three isoforms of CDases have been identified and classified by 
their pH optima as acidic, neutral and alkaline CDases. These CDases are located at the plasma membrane, 
lysosome, and ER/Golgi complex, respectively [100]. These enzymes hydrolytically cleave Cer in fatty acid 
and sphingosine (Sph). Notably, Sph origin is exclusively catabolic, since it only derives from sphingolipids 
degradation [101]. 
Cer-derived Sph can be recycled or undergo phosphorylation in position C1 with the generation of 
sphingosine-1-phosphate (S1P) by sphingosine kinases (as described below). S1P can be metabolized 
through the irreversible cleavage in position C2-C3, to hexadecenal and phosphoethanolamine in a reaction 
catalyzed by the S1P lyase enzyme, located on the ER cytosolic side [102]. This reaction, and the SPT 
catalyzed one, are the reactions of the entire sphingolipid metabolism which occur in only one direction, the 
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enzymes catalysing the opposite reaction being absent. S1P can also be dephosphorylated back to Sph 
through a reaction catalyzed by either lipid phosphate, or S1P specific phosphatases [103-105]. 
The products obtained from the sphingolipids degradation such as saccharide residues, fatty acids and, 
particularly, sphingosine can be reused for the synthesis of complex sphingolipids. In this process of 
recycling, sphingosine produced from SM and GSL catabolism reaches the RE where it is N-acylated to Cer. 
Cer can then be used for the biosynthesis of complex sphingolipids, as described in de novo biosynthesis. 
This pathway is called "salvage pathway" [82]. The sphingosine recycling process is an energy advantage to 
cells and, in different cell types, such as cells of glial origin, may constitute the principal pathway of 
sphingolipids synthesis [106]. 
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Figure 7. Schematic representation of sphingolipid metabolism (modified image from Ogretmen et al. [107]). 
SPT, serine-palmitoyl transferase; KSR, ketosphinganine reductase; CS, ceramide synthase; DES, dihydroceramide 
desaturase; GCS, glucosylceramide synthase; GlcCDase, glucosylceramidase; CGT, ceramide galactosyl transferase; 
GalCDase, galactosylceramidase; C1PP, ceramide-1-phosphate phosphatase; CK, ceramide kinase; SMS, 
sphingomyelin synthase; PC, phosphatidylcholine; DAG, diacylglycerol; SMase, spingomyelinase; SK, sphinosine 
kinase; S1PP, S1P phosphatase. 
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2.2 Sphingolipids: signal transduction molecules 
As described above, sphingolipids are ubiquitous membrane components, particularly abundant in the 
plasma membrane. In this context, sphingolipids physico-chemical properties enable them to fulfil and 
regulate a wide spectrum of relevant biological functions including molecular sorting, cell-cell interaction and 
intracellular transport. Indeed, membrane sphingolipids through their hydrophilic portion are able to 
recognize and interact with elements of the extracellular microenvironment (protein or oligosaccharide 
component of other cells), allowing the transfer of the information in the intracellular compartment. 
Furthermore, different stimuli applied to the cells (UV radiation, chemotherapy, growth factors, etc.) generate 
metabolic reactions that lead to the production of different intermediate of sphingolipid metabolism (Sph, 
S1P, Cer, GlcCer and Cer1P), acting as bioactive molecules involved, as intra- or extra-cellular messengers, 
in the regulation of crucial processes as cell growth, death, migration and senescence [83]. 
Sphingolipid signalling is a very complex and sophisticated network of cellular pathways highly regulated and 
interconnected to each other. Indeed, sphingolipid metabolism can be modulated by a large number of 
activators, and different metabolic pathways, even activated by the same stimulus, are involved in the 
production of the bioactive sphingoid molecules. In addition, the sphingolipid pathways also interact with 
other cellular signalling systems; these interactions can result in activation, synergism or antagonism. 
Enzymes involved in the sphingolipid metabolism are closely related, generating a complex interconnected 
network that serves not only to regulate the levels of individual bioactive lipids, but also their metabolic 
interconversion. The regulation of one single process can lead to variations in the levels of molecules that 
possess opposite biological functions. So the single bioactive molecule levels are relevant, but the balance 
between the levels of different molecules is more important. 
This complexity is also enhanced by the different isoforms and the different subcellular localization of the 
enzymes involved in the sphingolipid metabolism. In addition, sphingolipids have a poor solubility in the 
cytosol, due to their hydrophobic nature, therefore transport mechanisms are necessary to move, transfer an 
finally locate the different sphingolipids in a specific subcellular site (where the enzymes of their synthesis 
and degradation and potential targets involved in sphingolipid-mediated signalling are located) or in the 
extracellular milieu. Therefore intracellular levels of bioactive sphingolipids and, consequently, the effects on 
biological response depend not only from the functioning and location of key enzymes of their metabolism, 
but also from transport mechanisms [82,83]. 
Sphingolipid signalling involves different types of sphingoid biomediators including S1P and Cer identified as 
important regulators of numerous cellular processes. 
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Cer and S1P emerged as critical modulators of cell survival and death. It has been shown that several 
growth factors stimulate the production of S1P which functions as a mitogenic molecule, favouring 
proliferation and cell survival [108]. On the other hand, it has been demonstrated that many stress agents 
can increase endogenous Cer, but also Sph levels, which in turn mediate anti-proliferative responses 
inducing cell cycle arrest and apoptosis [109,110]. 
The evidence that these molecules are interconvertible with each other and exert opposing effects on cell 
survival gave birth to the concept of the sphingolipid rheostat, which postulated that the dynamic ratio 
between ceramide toward S1P determines cell fate (Fig. 8) [111]. 
Given the role of the sphingolipid rheostat in regulating growth and death, it is not surprising that sphingolipid 
metabolism is often found to be deregulated in cancer, a disease characterized by enhanced cell growth and 
reduced cell death. A growing body of evidence has implicated Cer, S1P and the genes involved in their 
synthesis, catabolism and signalling in various aspects of oncogenesis, cancer progression and drug- and 
radiation resistance. In relation to their influence over cell fate, Cer and S1P are considered as tumour-
suppressor and a tumour-promoting lipid respectively [107,112]. 
 
 
 
 
Figure 8. The sphingolipid rehostat 
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2.3 Cancer-suppressing role of Ceramide 
Cer is known to play an important role in the evolution of neoplasia, being intimately involved in the 
regulation of mechanisms that control growth arrest, differentiation, senescence and cell death [109,113]. 
Many anticancer drugs, such as etoposide, cannabinoids and daunorubicin [114-116], and other stress-
causing agonists, such as inducers of apoptosis, like FAS ligands [117], cause an increase of the 
endogenous Cer levels through the de novo synthesis. Furthermore the tumour necrosis factor α (TNF-α) in 
breast cancer cells [118] and ethanol in hepatoma cells [119], cause an increase in the endogenous Cer 
levels through the induction of the SM hydrolysis by SMases. 
Of interest, the accumulation of reactive oxygen species (ROS) induces activation of acid SMase, linking 
oxidative stress to Cer formation [120]. In this context, Santana and co-workers demonstrated that mice 
deficient in acid SMase lose the ability to accumulate Cer and acquire resistance to radiation-induced 
apoptosis [121]. 
On the other hand, decreased levels of endogenous Cer caused by an increased expression of GCS, which 
reduces Cer levels by incorporating it into GlcCer, results in the development of a multidrug resistance 
phenotype in many cancer cells [122]. 
Cer act as an intracellular messenger regulating many intracellular effectors that mediate the activation of 
the apoptotic process. In particular, Cer is able to activate the serine/threonine protein phosphatases PP1 
and PP2A. These phosphatases act on several substrates such as retinoblastoma protein (pRB), Bcl-2, c-
JUN, PKCα, SR proteins and Akt which are all implicated in cell pathways regulating proliferation and 
apoptosis. Cer-mediated activation of PP1 seems to be involved in the cell cycle arrest in the G1 phase, due 
to the dephosphorylation of pRB [107,123]. Furthermore PP1 induces the dephosphorylation of SR proteins, 
a family of serine/arginine-domain proteins and known modulators of mRNA splicing, thus inducing the 
alternative splicing of the genes encoding Bcl-X and caspase-9, generating pro-apoptotic splice variants 
[117,124]. Mitochondrial membrane potential can also be altered by Cer, probably through the PP2A-
mediated dephosphorylation of Bcl-2, causing its inactivation and thus favouring the apoptotic process [125]. 
Cer also activates Cathepsin D protease which in turn recruits and activates, via proteolytic breakdown, the 
pro-apoptotic protein BID resulting in the induction of apoptosis [107].  
Another important Cer target is PKC-ζ. Increased levels of Cer induce the activation of this protein, by 
phosphorylation. The activated PKC-ζ, in turn phosphorylates the hnRNP A1 factor, involved in the 
mechanisms of alternative splicing. This factor might be involved in the alternative splicing of genes involved 
in apoptosis [110]. 
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Cer can also exert an antiproliferative role through the inhibition of MAPK pathway, promoting the 
dephosphorylation of ERK1/2 (extracellular signal regulated protein kinase 1 and 2), serine/threonine 
kinases belonging to the family of MAP kinase (MAPK) [126]. These proteins, if dephosphorylated, are 
inactive and thus not able to migrate into the nucleus to promote the expression of genes involved in cell 
proliferation [127,128]. ERK1/2 inhibition induced by Cer can be associated with the ability of this mediator to 
activate, in systems "cell free", the serine/threonine protein phosphatase PP2A [129-131]. 
Cer can self-associate in the plane of the membrane bilayer and then fuse with GSLs- and cholesterol-
containing rafts resulting in the formation of signalling platforms [132]. Many stimuli activating acid SMase at 
the plasma membrane induce the formation of Cer-enriched domain that trap and cluster signalling proteins 
[132]. In these domains the initial signal can be amplified via concentration and oligomerization of proteins 
that transmit signals across the plasma membrane. Such clustering has been shown for proteins associated 
with apoptotic signalling. Fas receptors, Fas-associated death domain-containing protein (FADD) and 
caspase-8 have been shown to cluster within Cer-enriched domain [133]. Furthermore, Cer can induce 
apoptosis by forming membrane channels in mitocondria which are large enough to cytochrome c release 
[134]. 
 
 
2.4 Ceramide in glioblastomas 
Cer is known to play an important role in the evolution of neoplastic tumours, being involved as a mediator in 
the signal transduction mechanisms that control growth arrest, differentiation, senescence and cell death. 
In gliomas the involvement of an altered regulation of the Cer-mediated signalling pathways is strongly 
supported by the evidence of an inverse association between Cer intracellular levels and the progression of 
the tumour malignancy: a lower content of Cer corresponds to a higher grade of malignancy. It was also 
demonstrated that Cer levels are directly related to patient survival: a low intracellular Cer content is a 
negative prognostic factor [135]. 
The metabolic pathways involved in the control of Cer levels in glial cells include enzymes of its metabolism 
(SMS, SPT, SMases) and its transport from the ER to the Golgi apparatus for the biosynthesis of complex 
sphingolipids.  
It has been demonstrated that, in glioma cells, the administration of ∆9-tetrahydrocannabinol, the main active 
ingredient in marijuana, induces an accumulation of Cer in the ER through the stimulation of the "de novo" 
synthesis, resulting in apoptotic cell death [136]. Furthermore, the anti-proliferative effect of nitric oxide in 
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glioma cells is associated to the inhibition of Cer vesicular transport from the ER to the Golgi apparatus 
[137]. Of interest, in glioma cells the PI3K/Akt signalling is able to regulate the sphingolipid metabolism 
promoting Cer vesicular transport, resulting in a reduction of the intracellular levels of this molecule and an 
increased synthesis of complex sphingolipids [138]. 
Moreover, Cer-mediated caspase activation has been implicated in the γ-radiation-induced apoptosis in 
U87MG glioma cells lacking functional p53 [139]. In the same cell line, TNF-α activates both neutral and acid 
SMases in a p53-mediated ROS-dependent or -independent pathway that results in Cer production, which, 
in turn, induces apoptotic cell death [140].  
Interestingly, Cer induces not only apoptosis but also caspase-independent and/or non-apoptotic cell death 
in glioma cells. It has been demonstrated that administration of C2-Cer results in non-apoptotic cell death 
induction that can be inhibited by the constitutive active form of Akt [141]. It has been shown that C2-Cer 
induced cell death via autophagic mechanisms [142] and natural Cer has been recently implicated in 
cannabinoid-induced and in TMZ-induced autophagic death in U87MG and T98G glioblastoma cells, 
respectively [143].  
All this evidence suggests that the modulation of Cer intracellular levels can be crucial in determining the 
survival or death of the glioma cells. Many anticancer drugs cause an increase of the intracellular Cer levels. 
Consequently, tumour cells that possess an aberrant Cer metabolism develop resistance to these cytotoxic 
treatments, thereby determining their clinical failure.  
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3. SPHINGOSINE-1-PHOSPHATE 
 
In just over one decade the sphingoid molecule S1P has emerged as a key regulator of numerous 
physiological functions [144]. S1P is an intermediate of sphingolipid metabolism and its levels inside cells are 
finely regulated through the modulation of different enzymes responsible for its synthesis and degradation 
[145]. S1P is formed from sphingosine (Sph) and ATP in a reaction catalyzed by two isoenzymes, 
sphingosine kinase 1 (SK1) and sphingosine kinase 2 (SK2) [146]. As described above, S1P can be 
metabolized through two different pathways: i) the dephosphorylation back to Sph, catalyzed by either lipid 
phosphate phosphatases or S1P specific phosphatases [103,104]; ii) the irreversible cleavage by S1P lyase, 
to hexadecenal and phosphoethanolamine [102]. 
Although a simple molecule in structure (Fig. 9), S1P functions are complex. In particular, different studies, 
performed in both cell cultures and animals, demonstrate that it can regulate different physiological and 
pathological processes strictly related to cancer and inflammation, favouring cell growth, survival, migration, 
and angiogenesis [82,144]. S1P can exerts its bioactive properties intracellularly, acting as a second 
messenger, and, mainly in the extracellular milieu, where, after secretion from cells, it acts as a ligand for 
specific cell surface receptors [147].  
Relatively high concentrations of S1P are constitutively present in body fluids, while lower levels are 
detectable in tissues [148]. In particular, S1P is abundant in serum (300-500 nM) where it is mainly 
associated with serum proteins, such as lipoproteins (high density lipoprotein) and albumin [149]. 
 
 
 
 
Figure 9. S1P chemical structure [145]. 
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3.1 Sphingosine kinases 
S1P is formed from sphingosine and ATP in a reaction catayzed by the enzyme sphingosine kinase (SK). So 
far two isoenzymes, known as SK1 and SK2, have been identified in mammals. 
Both SKs are members of the diacylglycerol kinase family, containing five conserved domains responsible for 
substrate binding and catalytic activity. This structural homology is accompanied by SK1 and SK2 ability to 
catalyze the synthesis of the same product, S1P. Despite this evidence, SK1 and SK2 display different 
subcellular localization, tissue distribution and temporal expression pattern during development [146]. 
In humans, the gene coding for SK1 is located on the chromosome 17 (17q25.2), while the gene for SK2 is 
located on chromosome 19 (19q13.2) [151]. SK1 and SK2 are highly homologous (Fig. 10) and both contain 
five conserved domains (C1-C5), with the catalytic site located within the domains C1-C3 and the ATP 
binding site in the C2 domain. Although SK1 and SK2 display an 80% amino acid sequence similarity, they 
differ in their central region and N-terminus. SK1 lacks transmembrane domains or identifiable signal 
sequences and is mainly cytosolic. SK2 is about 240 amino acids longer than SK1 at its N-terminus and 
contains several transmembrane domains. In addition, SK2 possesses a nuclear localization signal in the N-
terminal region, which if mutated, prevents it from entering the nucleus and inhibiting DNA synthesis 
[151,152]. Furthermore, both SKs have a broad and different tissue distribution, with SK1 mainly expressed 
in lungs, brain and spleen and SK2 predominating in the heart, brain and liver [146]. 
 
 
 
 
Figure 10. SK1 and SK2 structure [150]. 
 
 
In addition, analysis carried out by northern blot showed a different SK1 and SK2 expression during the 
development process, in particular SK1 transcript is the first to be encoded, while only thereafter SK2 
transcript is observed [151].  
It has been demonstrated that both SKs have alternative spliced variants differing in their N-terminus. In 
particular SK1 has three alternative isoforms (SK1a,b,c), all with similar enzymatic properties and consisting 
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of 384, 398 and 470 amino acids, respectively. Also SK2 has two spliced variants, the N-terminally extended 
(SK2-L) and the smaller (SK2-S), composed of 618 aa and 654 amino acids, respectively [153]. 
Finally, SK1 and SK2 differ also in the substrate affinity. Indeed SK1 has a higher affinity to D-erythro-Sph 
(deriving from the "recicling" sphingolipid biosynthesis); on the contrary, SK2 has a higher affinity to D-
erythro-dhSph (deriving from the "de novo" sphingolipid biosynthesis). Furthermore, SK2 has a broader 
substrate specificity as it can also phosphorylate: phytosphingosine, DL-treo-dhSph (a SK1 inhibitor) as well 
as the immunomodulatory Sph analogue FTY720 [153,154]. 
The Km of the human SphK-1 and SphK-2 for D-erythro-Sph are comparable (15.6 mM and 13.8 mM 
respectively), and their pH optima are in the neutral range [149,153]. 
 
 
3.2 Regulation and functional roles of SKs 
Several extracellular stimuli are able to stimulate SK1 activation. In particular growth factors such as PDGF, 
EGF, VEGF, bFGF, IGF -1, nerve growth factor (NGF), TGF-β, cytokines such as TNF-α, interleukins and 
hormones play a key role in this process [151]. 
These molecules activate SK1 by inducing its phosphorylation on Ser225 residue in a PKC- and ERK- 
dependent manner. This leads to to SK1 translocation from the cytosolic compartment to the plasma 
membrane. In particular, the Ser225 phosphorylation causes a SK1 conformation change with the  
consequent exposure of the amino acids Asn84 and Thr54 present in the membrane binding domain,  
allowing SK1 binding to phosphatidic acid (PA) and phosphatidylserine (PS) located in the the cytosolic side 
of the plasma membrane [82,155-157]. Furthermore it has been demonstrated that SK1 conformational 
change allows its interaction with cytoskeletal proteins, such as Filamin A, which facilitates the process of re-
localization of the enzyme [158]. Moreover, it has been recently shown that, once phosphorylated, SK1 
relocalizes in particular portions of the plasma membrane called "lipid rafts" [158]. The localization in the 
plasma membrane allows SK1 interaction with its substrate, Sph, which is localized mainly at the level of the 
inner sheet of the plasma membrane [159]. Thus SK1 translocation to the plasma membrane is essential for 
Sph phosphorylation and consequent generation of S1P. 
Much less is known about SK2. Its activation mechanisms are not fully understood. It has been reported that 
in mast cells SK2 can be activated upon crosslinking with the high affinity IgE receptor (FcεRI), or with the 
Src protein tyrosine kinase Fyn [158,160,161]. Of note, also EGF is able to activate SK2 and induces 
phosphorylation on Thr578 and Ser351 amino acid residues, both dependent on ERK 1 [158,162]. 
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SK2 localizes primarily in the nucleus, where it is involved in cell cycle arrest. Of interest, SK2 
overexpression suppresses growth and enhances apoptosis, preceded by cytochrome c release and 
activation of caspase-3 [163]. Indeed, SK2 contains a BH3 domain that sequesters Bcl-XL, and abrogates its 
anti-apoptotic function. Therefore, SK2 can be pro-apoptotic [164]. 
However, the role of SK2 remains controversial, as it has been reported that SK2 protects MCF-7 breast 
cancer cells and HCT116 colon cancer cells from doxorubicin-induced apoptosis by a pathway mediated by 
p53-independent up-regulation of p21 [165]. SK2 plays a crucial role also in the regulation of the immune 
system response. The immunosuppressive Sph analogue FTY720 is phosphorylated in vivo primarily by SK2 
with the generation of FTY720-P. This compound inhibits the outcome of T lymphocytes from the secondary 
lymphoid organs, desensitizing S1P receptor S1P1 [159,166]. 
An increasing number of evidence demonstrates that SKs enzymes can be released from cells in the 
extracellular microenvironment; in this way it is possible to observe S1P production outside the cell.  
It has been reported that SK1 release occurs both in normal and in neoplastic cells. An active form of SK1 is 
constitutively released by vascular endothelial cells, contributing to the vascular S1P endothelial gradient. 
The mechanism of SK1 release seems to occur via non classical pathway independent of the ER/Golgi 
system, but one that requires functional actin dynamics [167,168]. Rigogliuso and colleagues demonstrated 
that SK1 can be released also by cells derived from human hepatocarcinoma and human breast carcinoma 
as component of membrane vescicles [169]. However, the precise mechanism by which SK1 is released in 
the extracellular milieu remains controversial and is still under investigation. 
SK2 release has been observed during apoptosis [170]. In particular, during human T cells, monocytes and 
human embryonal kidney (HEK293) cell death, an enzymatically active SK2 is released upon N-terminal 
truncation, a process demanding caspase-1 activation. Since S1P is vital for lymphocyte recruitment, 
Weigert an colleagues propose apoptotic cells as a local source for S1P, fundamental lipid mediator that 
affects immune cell attraction and activation. 
Once in the extracellular environment, both SK enzymes appear to use as substrates the Sph resulting from 
the degradation of SM present in the extracellular leaflet of the plasma membrane, and the ATP released by 
cells [171]. 
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3.3 Intracellular S1P 
Despite the S1P role as an extracellular mediator is well defined, little is known about the S1P role in the 
intracellular compartment. S1P can exert its bioactive properties also intracellularly, acting as a second 
messenger. However, intracellular S1P targets are still unidentified. It has been demonstrated an 
involvement of S1P in the induction of cell proliferation and suppression of the cell death process 
independently of S1P receptors. Interestingly, microinjection of S1P into fibroblasts increases calcium 
mobilization from internal stores, DNA synthesis, enhancing proliferation and survival [172]. S1P role as an 
intracellular messenger has been also suggested by some indirect evidences, such as the PDGF-induced 
translocation of SK to the nuclear membrane with the concomitant increase in the nucleus-associated SK 
activity [147]. This implies that S1P may have a role in the nucleus, and it was suggested that it may be 
involved in cell cycle progression, although no direct evidence for this has yet appeared. S1P has also been 
shown to activate ERK and inhibit c-Jun N-terminal kinase (JNK) activation, which is significant since the 
balance of ERK and JNK activation has been implicated in the control of apoptosis [147].  
Overall, and in contrast to the well-established actions of S1P through its receptors, the intracellular roles of 
S1P are poorly documented, and the identification of its direct intracellular targets remains elusive. 
 
 
3.4 Extracellular S1P: release and receptors  
S1P exerts its properties of bioactive molecule predominantly in the extracellular milieu. Of interest, it has 
been reported that S1P can be released especially from blood cells, such as platelets, red blood cells, 
neutrophils, mast cells and vascular endothelial cells [173]. Intriguingly, evidence on the constitutive export 
of S1P by cerebellar granule cells and astrocytes [174,175] supports the view that also nervous system cells 
can be an origin of S1P in the extracellular milieu. 
Intracellularly synthesized S1P is not able to permeate the plasma membrane due to its polar nature. This 
evidence suggests the need for active transport mechanisms. Although the mechanism of S1P release from 
cells is not completely understood, recent studies have demonstrated that S1P can be released by the ATP-
binding cassette (ABC) family transporters [86,173]. This family of membrane proteins is characterized by 
the presence of two transmembrane domains, each consisting of 6-11 membrane spanning α-helix, and two 
nucleotide binding domains (NBD), exposed to the cytoplasm. The two transmembrane domains define a 
channel through the plasma membrane. After its binding to the NBD, ATP provides the energy required to 
actively transport substrates across the membrane.  
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In the human genome 49 genes coding ABC transporters have been identified. On the basis of their 
sequence homology and NBD organization, human ABC transporters have been classified into seven 
subfamilies, designated A-G. ABC proteins have been generally recognized as drug efflux pumps that 
protect the body from various toxic substances, thus being implicated in the onset of drug resistance in 
different types of cancer. However they exhibit scarce selectivity and are able to move various molecules 
against their concentration gradient [176]. Increasing evidence supports that different subfamilies of ABC 
transporters are involved in sphingolipids passage across the plasma membrane.  
In particular ABCG2, ABCA1 and ABCC1 have been implicated in the S1P transport to the extracellular 
milieu in breast cancer cells, astrocytes, platelets, mast cells and vascular endothelial cells [173,177-180]. 
Despite this evidence the precise mechanism underlying S1P secretion is not yet well defined and is still 
under investigation. 
Once released, S1P can interact, in an autocrine and/or paracrine manner, with five specific transmembrane 
receptors (S1P1-5) coupled to different G-proteins and displaying tissue-specific expression patterns [181]. 
Through this interaction S1P can activate several signal transduction pathways, and thus elicit a variety of 
cell-specific responses controlling cell behaviour [166]. 
The transcript for S1P1 receptor has been cloned as an immediate-early gene induced during differentiation 
of human endothelial cells into capillary-like tubules, an in vitro model of angiogenesis. Thus, S1P receptors 
have been initially named EGD (Endothelial Differentiation Gene) receptors [182]. All the five receptors bind 
S1P (and dhS1P) with high affinity. Unphosphorylated Sph, and its derivates (Sph, DHSph or Cer) are 
unable to compete with the binding of S1P [183]. 
The S1P receptors are ubiquitously, but differently expressed in all cells, and are coupled to a variety of 
heterotrimeric G protein. The cell type specific expression of S1P receptors, as well as their differential 
coupling to different G proteins, contribute to the S1P ability of regulating different cellular processes in a 
highly specific manner. 
The S1P1 and S1P4 couple mainly to Gi; both S1P2 and S1P3 activate Gi, Gq and G12/13; S1P5 is linked to Gi 
and G12/13 [150]. The activation of these G proteins results in the modulation of different signalling pathway 
such as ERK, c-Jun N-terminal kinase (JNK), the small GTPases of the Rho family (Rho and Rac), 
phospholipase C (PLC), adenylate cyclase-cAMP, and PI3K/Akt signalling [149,150,166] (Fig. 11). Through 
its receptors, S1P is able to regulate different cellular processes, such as cell proliferation, motility, invasion, 
cytoskeletal rearrangement, angiogenesis, vascular maturation and lymphocyte trafficking and actions 
[149,150]. 
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S1P1 is ubiquitously expressed, with high levels in brain, lungs, spleen, heart and kidneys. It plays a key role 
in angiogenesis and vascular maturation, regulation of immune cell trafficking, endothelial barrier function, 
and vascular tone. It has been demonstrated that, upon binding with S1P, S1P1 is able to trans-activate 
growth factor receptor tyrosine kinase (RTKs), such as VEGF, PDGF, and EGF receptors. This can occur 
through three distinct mechanisms: i) intracellular cross-talk and direct phosphorylation of RTK by protein 
tyrosine kinases; ii) induced production and/or secretion of growth factors; iii) participation of S1P1 and RTK 
in a signal complex, either by direct interactions or by binding of both receptors to scaffold proteins 
[149,150]. 
S1P2 is widely expressed in a variety of different cell types. It plays fundamental roles in the cardiac 
development, and in the development and maintenance of neuronal excitability [149]. Furthermore, this 
receptor is required for proper development of the auditory and vestibular systems, and for proper 
degranulation of mast cells. S1P2 can exert a negative role in the regulation of cell migration, and 
overexpression of S1P2 is able to inhibit S1P-induced cell migration [184]. For this reason it is considered to 
be a repellent S1P receptor, and appears to work in opposition to S1P1 and S1P3, both enhancing cell 
migration [185]. Finally, S1P2 activation leads to an increased vascular permeability through ROCK/Rho 
activation [181]. 
S1P3 is abundantly expressed in the cardiovascular system, lungs, spleen, kidneys, intestines and cartilage. 
This receptor is an important regulator of vascular permeability through the downstream effectors ROCK and 
Rho proteins. A clear role for S1P3 has also been demonstrated in the regulation of the heart rate, as its 
expression is localized in myocytes and perivascular smooth muscle cells, and its activation results in 
bradycardia and hypertension. Furthermore, S1P binding to this receptor has been shown to enhance cell 
survival by suppression of Bax expression and activation of endothelial NOS, PI3K and Akt [147,181]. 
S1P4 is primarily expressed in lymphoid tissues, including thymus, spleen, bone marrow and peripheral 
leukocytes. S1P4 stimulation activates ERK1/2, phospholipase C and modulates the opening of intracellular 
calcium stores. This receptor seems to be implicated in the regulation of T-cell migration and cytokine 
production [149,186]. 
S1P5 is highly expressed in the brain, in particular in oligodendrocytes. The binding to S1P induces a 
phosphatase dependent inhibition of ERK 1/2, resulting in an antiproliferative phenotype. Recently it has 
been demonstrated that this receptor is present in Natural Killer cells (NK) and is involved in the homing and 
mobilization of these cells to inflamed organs [147,186].  
 
 43 
 
 
Figure 11. Signal transduction pathways activated by S1P receptors (modified image from Spiegel et al. [150]) 
AC, adenylate cyclase; JNK, c-Jun N-terminal kinase; PLC, phospholipase C. 
 
 
3.5 Cancer-promoting roles of S1P 
Cancer is a disease characterized by a total alteration of normal cellular processes that govern cell 
proliferation and normal cellular homeostasis. These alterations allow tumour cells to acquire a malignant 
phenotype and survival advantages.  
A growing body of evidence has implicated S1P and SK1 in various aspects of oncogenesis, both favouring 
cell survival, migration, angiogenesis and drug resistance, thus identifying a fundamental role of these two 
molecules in the onset of cancer (Fig. 12) [107,187]. 
 
Cell survival 
SK1 has emerged as an oncogene, found overexpressed in multiple types of cancer including brain, colon, 
lung and kidney tumours, compared with their healthy counterparts and associated with tumour grading as 
well as reduced patient survival [188,189]. In agreement, the down-regulation of SK1 expression in cancer 
cells reduces growth and increases apoptosis [190]. Xia and colleagues [191,192] demonstrated that SK1 
overexpression in murine 3T3 fibroblasts causes cell transformation in culture and tumour onset in SCID 
mice. Moreover, SK1 overexpression in MCF-7 breast cancer cells increases cell proliferation and DNA 
synthesis, accelerates G1/S transition of the cell cycle, and enhances estrogen-dependent tumorigenesis 
[193]. In addition, SK1 overexpression in non-tumorigenic pro-erythroblasts increased their clonogenicity as 
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well as resistance to apoptosis, suggesting that high expression of SK1 may be an oncogenic event required 
for progression of erythroleukemia [194].  
S1P has emerged as an onco-promoter molecule. Interestingly, the administration of S1P to different cell 
types results in the inhibition of different forms of cellular apoptosis, including the Cer-mediated one [111], 
through the induction of pro-survival proteins expression (Bcl-2, MCL1), stimulation of the DNA replication, 
and inhibition of pro-apoptotic proteins expression (Bad, Bax). Exogenous S1P also blocks the translocation 
of Bax to the mitochondria, which is required for the release of mitochondrial cytochrome c and the 
consequent caspase activation [187]. 
S1P was also shown to promote estrogen-dependent tumorigenesis of MCF-7 human breast cancer cells 
[193]. Johnson and colleagues used siRNAs to show that inhibition of S1P phosphatase 1 (S1PP1), which 
converts S1P to sphingosine, results in increased intracellular and extracellular levels of S1P and endows 
MCF-7 cells with resistance to the cytotoxic actions of TNFα and daunorubicin [195]. 
 
Cell motility 
S1P stimulates the motility of cancer cells through S1P1 or S1P3. By contrast, S1P can inhibit cancer cell 
motility through S1P2-dependent regulation of Rho. The specific effect of S1P is partly determined by the 
predominance of the receptor subtypes expressed. For example, S1P stimulates the migration of gastric 
tumour cells that exclusively expressing S1P3 and inhibits the motility of others that predominantly express 
S1PR2 [196]. 
Similarly, the inhibition of melanoma cell migration is through S1P2 and involves the inhibition of Rac, 
activation of Rho, and the subsequent tyrosine phosphorylation of focal adhesion kinase and paxillin as well 
as the increment of stress fibre formation [197,198]. 
On the other hand, S1P stimulates the migration of fibrosarcoma cells through a S1P1–Rac1–CDC42-
dependent pathway involving the tyrosine phosphorylation of membrane type matrix metalloproteinase 1 
(MT1-MMP), a zinc-dependent proteolytic enzyme involved in degradation of the extracellular matrix, 
facilitating cell migration [199,200]. Furthermore, ovarian cancer cell invasion induced by S1P involves 
S1PR1 or S1PR3 and calcium mobilization [201]. 
Of interest, the pharmacological inhibition of both SKs suppresses chemotaxis following growth factor 
stimulation in diverse cell types [188]. In particular, in breast cancer cells the down-regulation of both SK1 
and SK2, suppresses EGF-induced migration, while overexpression of either SK1 or SK2 enhances 
migration towards EGF [202]. A link between S1P signalling, cell migration and tumour metastasis was 
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uncovered when it was observed that the overexpression of the KAI1 gene down-regulates SK1. The KAI1 
gene was originally isolated as a prostate-specific tumour metastasis suppressor gene that inhibited 
metastases without affecting primary tumour formation. The KAI1 overexpression in pancreatic carcinoma 
cells significantly reduced both SK1 activity and cell migration [203]. 
 
Tumour angiogenesis 
Angiogenesis plays a key role in providing oxygen and nutrients to the tumour mass, as well as a direct 
access to the bloodstream, thus facilitating the generation of metastasis. An increasing number of evidence 
demonstrated that S1P acts as a potent pro-angiogenic factor, inducing the migration of endothelial cells and 
promoting the formation of new blood vessels. 
The mechanisms of S1P-mediated neovascularization involve the migration of endothelial cells through the 
activation of S1P receptors, and downstream regulation of the RHO family of small GTPases, which in turn 
regulate cell motility and remodelling of the cytoskeleton [204]. The main S1P receptor involved in the 
process of vascular maturation is S1P1, which is required for the stabilization of nascent blood vessels during 
embryonic development, indeed its knockout in mouse resulted in a lethal vascular defect [205].  
S1P1 expression is enhanced in lung carcinoma vasculature during angiogenesis, and its knockdown inhibits 
endothelial cell migration in vitro and the growth of neovessels into subcutaneous implants of Matrigel in 
vivo, resulting in the dramatic suppression of tumour growth [206]. These evidences strongly suggest that 
S1P1 is a crucial receptor in mediating angiogenesis and metastasis in tumours. 
There is also evidence that SK1 is involved in angiogenesis. Indeed, SK1 overexpression in endothelial cells 
enhances survival after serum deprivation and detachment from the extracellular matrix, suggesting that it 
may play an important role in vascular phenomena that occur under stress conditions [207].  
It has been demonstrated that there is a crosstalk between SK1 and the VEGF signalling, which is crucial for 
angiogenesis. In particular, VEGF was shown to stimulate SK1 activity in bladder tumour cells and, in turn, 
SK1-mediated VEGF-induced activation of Ras and MAPKs. Indeed, SK1 inhibition reduces VEGF-
stimulated MAPK activation in in these cancer cells [208]. As S1P is also secreted extracellularly, modulation 
of SK and S1P in tumour cells provides a potential mechanism for recruiting endothelial cells and promoting 
blood-vessel formation/angiogenesis [107]. Indeed, combining S1P with other pro-angiogenic factors, such 
as basic fibroblast growth factor or VEGF, produced synergistic enhancement of neovascularization in tissue 
samples of mouse aortic rings, an ex vivo model of angiogenesis [209]. 
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Drug resistance 
One of the main obstacles involved in cancer therapy is the development of drug resistance. A significant 
body of literature now implicates SK1/S1P signalling in this process, since it protects cancer cells from 
chemotherapy-induced apoptosis. For example, in prostate adenocarcinoma SK1 regulates drug-induced 
apoptosis and serves as a chemotherapy sensor both in culture and in animal models. In particular, SK1 
overexpression impaired the efficacy of chemotherapy (Docetaxel and Camptothecin). Alternatively, 
silencing SK1 by RNA interference or pharmacologic inhibition induced apoptosis both in vitro and in vivo 
[210]. 
In parallel with these data, increasing the expression of SK1, reduced the sensitivity of melanoma cells to 
Fas- and Cer-mediated apoptosis that could be reversed by the inhibition of SK1 expression [211].  
Furthermore, high expression levels of SK1 and S1PRs were detected in Camptothecin- (CPT) resistant 
prostate cancer cells. Specifically, inhibition of SK1 expression or S1PR signalling significantly inhibited cell 
growth, and treatment of these cells with CPT induced upregulation of SK1/S1PR signalling [212]. Moreover, 
it has been demonstrated that SK1 overexpresion increases proliferation and resistance to Tamoxifen of 
breast cancer cells, whereas siRNA knock down of SK1 restores Tamoxifen responsiveness [213]. Of 
interest, S1P-lyase, which irreversibly degrades S1P, was found to play a crucial role in the increased 
sensitivity of human colon cancer cells to apoptotic stimuli, in a p38- and p53- dependent manner [214]. 
Taken together, this evidence demonstrates a relationship between the changes in the S1P metabolism and 
development of drug resistance in human cancer cells. Therefore, one possible approach to overcome this 
resistance could be through modulation of the sphingolipid pathway [187]. Strategies that could be adopted 
to limit the effects of S1P signalling in cancer include the pharmacological inhibition of SK and targeting of 
S1P receptors. 
A number of novel inhibitors of human SK were identified. These compounds are antiproliferative toward a 
bladder and breast cancer cell lines, including those lines with the multidrug resistance phenotype, because 
of overexpression of either P-glycoprotein or multidrug resistance phenotype 1. Furthermore, each inhibitor 
induced apoptosis concomitant with tumour cell cytotoxicity [189]. The dimethylSph (DMS), a sphingosine 
analogue widely used as a pharmacological inhibitor for SK, inhibits leukaemia, colon, epidermoid and lung 
tumour cell growth and reduces metastasis in vivo [215,216]. DMS also increases the sensitivity of human 
leukaemia cells to apoptosis in response to radiation, TNF-α and FAS ligand [217]. Another Sph isomer, 
Safingol, induced apoptosis and increased the growth-inhibitory actions of Doxorubicin even in multidrug-
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resistant cancer cells. Safingol is under evaluation in Phase I trials for the treatment of various human 
cancers in combination with other chemotherapeutic agents such and Cisplatin [218]. 
However, these compounds, without SK isoform specificity, also inhibit PKC and Cer kinase, as well cause 
hemolysis and hepatotoxicity [219]. Since SK1 and SK2 may have different functions in cancer progression, 
the specific targets for these isoforms are needed. SK1-I (BML-258), a specific SK1 inhibitor, prevents 
tumour growth and vascularisation, and induces apoptosis in glioblastoma xenografts. In addition, SK1-I 
enhances survival in orthotopic glioblastoma [220]. Recently, a SK2-selective inhibitor (ABC294640) has 
been identified. It inhibits tumour growth, induces apoptosis and autophagic cell death in kidney tumour 
xenografts [221]. 
It has been demonstrated that the immunosuppressant Fingolimod (FTY720), an analogue of sphingosine 
currently used in multiple sclerosis treatment, has also anticancer effects. In particular, it is taken up by cells, 
phosphorylated to FTY720‑P by SK2 [154,222], and then released. Extracellular FTY720‑P can bind to S1P 
receptors (except S1P2), causing their rapid poly-ubiquitinylation, endocytosis and proteasomal degradation, 
thus inducing sequestration of T lymphocytes in lymphoid tissues [223,224]. In addition to its 
immunosuppressive function, FTY720 was shown to induce growth arrest and apoptosis in leukemia, 
bladder, prostate, breast cancer, and also glioma cells [225-228]. Furthermore, FTY720 is able to prevent 
tumour growth and metastasis in mouse breast cancer cells, both in vitro and in vivo [229]. Of interest, 
FTY720 inhibits tumour vascularization and angiogenesis in vivo, in both hepatocellular carcinoma and 
prostate cancer, through the functional antagonism of S1P1 in endothelial cells [230-232]. 
 
 
 
 
Figure 12. Summary of S1P roles in tumorigenesis (modifierd image from Pyne et al.[187]). 
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3.6 S1P in gliobastomas 
A growing body of evidence has implicated S1P and the genes involved in its synthesis, catabolism and 
signalling in various aspects of oncogenesis, cancer progression and drug- and radiation resistance [107]. 
S1P has emerged as an onco-promoter molecule in different tumours, including GBM [173,187,233]. 
Notably, it has been previously documented that S1P enhances proliferation [234], motility, invasiveness and 
malignant behavior of GBM cells [235]. As an indication of the importance of this molecule, different studies 
have reported that GBM cell lines and tissue specimens show an high SK1 expression [236,237] which 
correlates with a worst prognosis and a poor patient survival [238] and that silencing or pharmacological 
inhibition of both SK1 and SK2 decreases the proliferation rate in GBM cells, preventing their entry into the 
cell cycle [236,238].  
It has been reported that glioma cells are able not only to produce S1P, but also to release it in the 
extracellular milieu [237,239]. This evidence suggests that S1P may play an important role as 
autocrine/paracrine messenger in GBM. 
Furthermore, it has been extensively demonstrated that glioblastoma cells commonly express S1P receptors, 
S1P1, S1P2, and S1P3 and very low levels of S1P5 [234,240,241], all contributing to GBM cell growth and 
invasion through distinct, but overlapping mechanisms. For example, it has been demonstrated that, through 
activation of S1P1, S1P up-regulates the expression of urokinase plasminogen activator (uPA), a potent 
stimulator involved in cancer cells invasion, in human glioblastoma multiforme cells [242]. 
 
 
3.7 S1P in glioblastoma stem cells  
Interestingly, in the last years S1P is emerging as an important mediator determining GSCs properties. 
Annabi and co-workers suggested for the first time that GSCs, isolated from a glioblastoma cell line, express 
S1P receptors (mainly S1P1) and that the exogenously added S1P promotes migration and invasivity of 
these cells in vitro via membrane-type-1 matrix metallopreoteinase MT1-MMP [243]. Furthermore, Mora and 
colleagues demonstrated that the treatment with a SKs inhibitor causes the dissociation of neurospheres, the 
structures usually formed by GSCs in culture, abolishing their growth and favouring cell death [244]. 
Estrada-Bernal and collaborators demonstrated that GSCs expressing a constitutively active EGF receptor 
mutant (EGFR vIII) are characterized by high levels of SK1 activity. EGFR inhibitors modestly decrease SK1 
activity and proliferation of these cells in culture. More extensive blockage of SK1 activity potently inhibits cell 
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proliferation and induces GSCs death. Thus SK1 activity is necessary for GSC survival, and EGFRvIII 
partially utilizes SK1 to further enhance cell proliferation [245]. 
Furthermore, a recent study demonstrated that the inhibition of S1P receptors, through the administration of 
FTY720, decreases GSCs viability and acts synergistically with TMZ in vitro. Moreover, in vivo FTY720 
promotes survival in a rodent model of GBM and decreases GSCs invasiveness in nude mouse brains [246].
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AIM OF THE WORK 
 
GBM is the most frequent, aggressive and deadly primary central nervous system tumour in humans [1]. 
Despite the introduction of the alkylating agent TMZ in glioblastoma therapy has improved patient survival, 
drug resistance mechanisms limit its benefits and the prognosis remains unfavorable [33]. Growing evidence 
suggests that GSCs, a cell subpopulation within the tumour, play a crucial role in the GBM malignant 
behaviour, being involved in the processes of chemo-resistance, recurrence, metastasis and angiogenesis 
[49,50,52]. However, the precise mechanisms underlying the chemoresistance and the malignancy of GSCs 
are not completely understood. 
A large amount of evidence demonstrates the role of S1P as an important tumour-promoting lipid, exerting 
its effects predominantly in the extracellular milieu after interaction with specific G protein-coupled receptors 
[144,173], thus favouring growth, invasion, and chemotherapy resistance of different cancer cells [247], 
including glioblastoma ones [235,248]. Recent pieces of evidence suggest that S1P could represent an 
important mediator of GSCs properties, too. Indeed GSCs do express S1P receptors and exogenously 
added S1P promotes migration and invasivity of these cells in vitro via MT1-MMP [243]. Furthermore, the 
inhibition of S1P biosynthesis results in the dissociation of neurospheres (the structures usually formed by 
GSCs in culture), in the arrest of proliferation, and in cell death [244,245]. 
Despite these promising findings, up to now the putative role of S1P as an autocrine/paracrine factor 
modulating GSCs survival has been poorly investigated. Notably it is still unclear if GSCs are able to produce 
and release their own S1P extracellularly, or if S1P secreted by other neighbour cells (such as neurons, 
astrocytes, endothelial cells and glioblastoma cells), is the real responsible for the S1P-mediated responses 
observed in GSCs. In this context, it is worth noting that neural stem cells have been shown to be unable to 
release S1P extracellularly, but S1P exhibits a potent chemo-attractant activity on these stem cells [249].  
On these premises, the aim of this PhD project was to investigate the ability of glioblastoma cells and GSCs 
to produce and release S1P in the extracellular milieu. Moreover, we evaluated the possible involvement of 
S1P as an autocrine/paracrine factor modulating TMZ resistance, with particular attention to S1P cross-talk 
with ceramide, a tumour-suppressor lipid exerting opposite effects on cell survival compared to S1P [111]. 
The overall rationale of this research was that a better understanding of S1P role in GSC aggressive 
phenotype could represent a critical start point that sets the bases for the development of new compounds 
able to modulate S1P metabolism in order to sensitize GSCs to chemotherapeutic treatments. 
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MATERIALS AND METHODS 
 
 
MATERIALS 
 
All reagents were of analytical grade. DMEM, L-glutamine, penicillin, streptomycin, amphotericin B, EGF, 
insulin, fatty acid free bovine serum albumin (BSA-FFA), 3-[4,5-dimethylthiazol-2-yl]2,5-diphenyl tetrazolium 
bromide (MTT), aprotinin, leupeptin, pepstatin, bestatin, Kodak Biomax film, D-erytrhro-sphingosine, C6-
ceramide (N-hexanoyl-D-erythro-sphingosine), C2-ceramide (N-acetyl-D-erythro-sphingosine), bovine brain 
ceramide and other common chemicals were from Sigma Aldrich (St.Louis, MO, USA).  
Fetal calf serum (FCS) was from EuroClone (Pero, Milan, Italy). bFGF was purchased from PeproTech 
(Rocky Hill, NJ, USA). B27 supplement, DMEM/F12 and Trypsin TrypLE Express were obtained from 
Invitrogen (Carlsbad, CA, USA). RNeasy mini kit and RNase-free DNAse I were from Qiagen (Valencia, CA, 
USA). iScript cDNA synthesis kit and SYBR green super mix were from Biorad Laboratories (Hercules, CA, 
USA). Temozolomide was from Schering-Plough (Segrate, Milan, Italy). Sphingosine-1-phosphate and 
primary mouse anti-ABCG2 antibody were purchased from Enzo Life Sciences (Farmingdale, NY, USA).  
Primary goat anti-MGMT antibody, primary mouse anti-ABCC1 antibody and mouse anti-goat horseradish 
peroxidase-linked secondary antibody were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Primary 
rabbit anti-SK1 and anti-SK2 antibodies were purchased from Abcam (Cambridge, UK). Primary mouse anti-
ABCA1 antibody was from Chemicon-Millipore (Billerica, MA, USA). Goat anti-mouse horseradish 
peroxidase-linked secondary antibody was from Thermo Fisher Scientific (Waltham, MA, USA). Goat anti-
rabbit horseradish peroxidase-linked secondary antibody, SuperSignal West Pico and West Femto Maximum 
Sensitivity Chemioluminescent Substrate were purchased from Pierce Chemical Co (Rockford, IL, USA). 
[3H]-D-erythro-sphingosine ([3H]-Sph) was from Perkin Elmer (Boston, MA, USA). [3H]-dihydrosphingosine 
([3H]-DHSph) was from American Radiolabeled Chemicals (St Louis, MO, USA). [γ-32P]ATP was from GE 
Healthcare (Milan, Italy). High performance thin layer chromatography (HPTLC) silica gel plates, and all 
solvents were purchased from Merck (Darmstadt, Germany). Sphingosine kinases inhibitor (SKI) was from 
Echelon Biosciences Inc. (Salt Lake City, UT, USA). 
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METHODS 
 
4.1 Cell cultures  
 
T98G glioblastoma multiforme cell line 
T98G human glioblastoma multiforme cell line was cultured in a humidified atmosphere at 37° C with 5% 
CO2 and expanded in vitro in DMEM containing: 10% (v/v) heat-inactivated fetal calf serum, 1 mM sodium 
pyruvate, 2 mM L-glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin and 0.25 µg/ml amphotericin B. 
The culture medium was changed every 48 hours. Cells were maintained by serial passages in 75 cm2 
culture flasks. When the culture reached confluence, subculture was prepared using a 0.025% trypsin–
0.01% EDTA solution. Cells were re-suspended in DMEM 10% FCS, counted by trypan blue dye exclusion 
test using a Neubauer emocytometer and then re-plated (13-26×103 cells/cm2).  
 
Temozolomide-resistant T98G cell line 
Temozolomide-resistant (TMZ-R) cells were obtained from T98G cells by gradual and repeated treatments 
with increasing concentrations of TMZ between 0.1 mM and 1.5 mM for 48 hours at each passage of 
duplication. In particular, at each step of selection, cells were exposed to a higher drug concentration as 
soon as re-growth was apparent. This kind of drug administration provides a selective pressure that leads to 
the survival of resistant cells no longer sensitive to therapy. In these conditions, a subpopulation of cells able 
to grow in the presence of 1.5 mM TMZ has been selected. 
Resistant cells were cultured as described for T98G cells and maintained by 24-hours exposure to 1.5 mM 
TMZ once every two passages of duplication.  
 
U87-MG glioblastoma multiforme cell line 
U87-MG human glioblastoma multiforme cell line was cultured in a humidified atmosphere at 37° C with 5% 
CO2 and expanded in vitro in DMEM containing: 10% (v/v) heat-inactivated fetal calf serum, 2 mM L-
glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin and 0.25 µg/ml amphotericin B. The culture 
medium was changed every 48 hours. Cells were maintained by serial passages in 75 cm2 culture flasks. 
When the culture reached confluence, subculture was prepared using a 0,025% trypsin–0.01% EDTA 
solution. Cells were re-suspended in DMEM 10% FCS, counted by trypan blue dye exclusion test using a 
Neubauer emocytometer and then re-plated (20-30×103 cells/cm2). 
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U-SC glioblastoma stem cells 
U-SC were isolated from the stable U87-MG cell line using a selective medium composed of DMEM/F12 
without serum and supplemented with 10 ng/ml bFGF, 20 ng/ml EGF, 5 µg/ml insulin, B27 supplement, 2 
mM L-glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin and 0.25 µg/ml amphotericin B. To this 
purpose U87-MG cells were plated in 100 mm Petri dishes at 3 x 103 cells/cm2 in 5 ml of selective medium 
and mantained at 37°C in a humidified atmosphere of 5% CO2 for one month.  
In order to obtain the progressive enrichment and stable expansion of U-SC in culture, during the isolation 
process every week neurospheres (the compact cell clusters floating in suspension usually formed by GSCs 
in culture) were subcultured by harvesting, followed by dissociation and re-plating under the same growth 
conditions. To this end the culture medium containing neurospheres in suspension was centrifuged at room 
temperature for 10 minutes at 280 x g. Subsequently, the cellular pellet obtained was incubated with Trypsin 
TrypLE Express, resuspended in order to obtain the complete cell dissociation and then cells were counted 
by trypan blue dye exclusion test using a Neubauer emocytometer. After a centrifugation at room 
temperature for 10 minutes at 280 x g, cells were resuspended in selective medium and re-plated in order to 
keep the process of selection. The expression of brain cancer stem cell markers was then evaluated in order 
to test the successful enrichment in U-SC of the cell population obtained by selective isolation.  
Once isolated, cells were maintained by serial passages in a humidified atmosphere at 37° C with 5% CO2 in 
75 cm2 culture flasks, using the same culture medium used during selection. Once a week neurospheres 
were dissociated and counted as described above and then re-plated (25x103 cells/cm2) to allow cell 
propagation. 
 
L0627 glioblastoma stem cells 
The GSC line L0627 was obtained from a post-surgery specimen of a primary human glioblastoma 
multiforme, as previously described [48]. L0627 were maintained at 37°C in 5% CO2 humidified atmosphere 
and expanded in vitro in a selective medium consisting of serum-free DMEM/F12 supplemented with: 10 
ng/ml bFGF, 20 ng/ml EGF, 0.6% glucose, 0.1% NaHCO3, 5 mM Hepes, 2 mM L-glutamine, 0.0004% 
heparin, 100 units/ml penicillin, 100 µg/ml streptomycin and 10X Hormone Mix  (consisting of DMEM/F12 
with the addition of: 0.6% glucose, 0.1% NaHCO3, 5 mM Hepes, 1 mg/ml apo-transferrin, 0.2 mg/ml insulin, 
0.1 mg/ml putrescine, 0.3 µM selenium and 0.2 µM progesterone) [250].  
Cells were maintained by serial passages in 75 cm2 culture flasks and when the neurospheres reached an 
average diameter of 100-300 µm, subculture was prepared (every 72-96 hours). To this purpose culture 
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medium containing cells in suspension was centrifuged at room temperature for 5 minutes at 194 x g. Cells 
were then disaggregated by mechanical dissociation, counted by trypan blue dye exclusion test, 
resuspended in culture medium and then re-plated (20×103 cells/cm2). 
 
PT 1 and PT 2 glioblastoma stem cells  
PT 1- and PT 2-GSCs were isolated at the Carlo Besta Neurological Institute, from GBM specimens obtained 
from two patients showing a different GBM aggressive phenotype (PT 1 and PT 2). Cells were maintained by 
serial passages in a humidified atmosphere at 37° C with 5% CO2 and 93% N2 (hypoxic conditions) in 75 cm2 
culture flasks. Cells were expanded in vitro in the same selective medium described for L0627 cells and 
when the neurospheres reached an average diameter of 100-300 µm, subculture was prepared. In particular, 
culture medium containing cells in suspension was centrifuged at room temperature for 10 minutes at 280 x 
g, cells were disaggregated by enzymatic dissociation (Trypsin TrypLE Express), counted by trypan blue dye 
exclusion test, resuspended in culture medium and then re-plated. 
 
All cell models were plated for experiments at the opportune density in tissue plate dishes (3.2 cm of 
diameter) or in 24/96-well plates (1.5 and 0.6 cm of diameter, respectively). 
 
 
4.2 RNA isolation, reverse transcription and Real-Time PCR  
Total RNA was isolated from U87-MG and U-SC cells with the RNeasy mini kit and treated with the RNase-
free DNAse I. One microgram of RNA was reverse transcribed using the iScript cDNA synthesis kit according 
to manifacturer’s instructions. Real-Time PCR was performed using the iQ5 Real-Time PCR detection 
system (Biorad Laboratories, Hercules, CA, USA). Specific SYBR green expression assays (SYBR green 
super mix) for CD133, nestin and GAPDH were carried out. Simultaneous amplification of the target 
sequences was performed as follows: 3 minutes at 95°C, 50 cycles 95°C 10 seconds, 58°C 40 seconds, 
60°C 10 seconds and 1 cycle 60°C 3 minutes. Results were analyzed using the iQ5 optical system software 
(Biorad Laboratories, Hercules, CA, USA). Relative gene expression was determined using the 2-∆∆Ct method 
[251]. Data were normalized to GAPDH expression (used as endogenous control) and U87-MG cells were 
used as calibrator.  
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4.3 Cell treatments 
For cell treatments, stock solutions were prepared by dissolving the different molecules as follows:  
- TMZ: 200 mM stock solutions were prepared in DMSO; 
- C2-Cer: 25 mM stock solutions were prepared in ethanol; 
- C6-Cer: 50 mM stock solutions were dissolved in ethanol; 
- Bovine brain Cer: 10 mM stock solutions were prepared in Ethanol/dodecane 98:2 (v/v); 
- SK inhibitor (SKI): 15 mM stock solutions were dissolved in DMSO; 
- S1P: 100 µM stock solutions were prepared in fatty acid free bovine serum albumin 4mg/ml in PBS 
and incubated for 30’ at 37°C with constant stirring before use. 
Stock solutions were diluted extemporaneously in fresh medium at the desired concentrations and 
administered to cells for the indicated period of time. Of relevance, ethanol and DMSO final concentrations in 
the culture medium were always maintained below 0.5%, concentrations that do not affect cell survival. In 
each experiment untreated cells were incubated with vehicles at the same final concentration of treated cells 
as controls. At the end of the treatments cell survival was evaluated by MTT assay. 
 
 
4.4 Analysis of cell viability 
Cell viability was determined by MTT colorimetric assay. U87-MG and GSCs were seeded at 1 x 104 and 2 x 
104 cells/cm2 respectively in 24- or 96-well plates. The day after cells were treated with different agents for 
the indicated periods of time. The medium was then replaced by MTT dissolved in fresh medium (0.8 mg/ml) 
for 4 hours. The formazan crystals formed in viable cells were then solubilized in iso-propanol/formic acid 
(95:5 v/v) for 10 minutes with constant stirring to ameliorate the lysis process. The absorbance at 570 nm 
was measured using a microplate reader (Wallack Multilabel Counter, Perkin Elmer, Boston, MA, USA). In 
some cases (see text), cell viability was also determined by trypan blue exclusion. 
 
 
4.5 Immunoblotting analyses  
Protein expression levels were evaluated using different conditions of cell lysis, SDS-PAGE and Western 
blotting depending on the antigen analysed, as described below. 
In all cases a small aliquot of cell lysates was analyzed for the protein content with the Comassie Blue-based 
assay. The remaining lysate was denatured by the addition of Sample Buffer 4X (containing 0.25 M Tris- HCl 
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pH 6.8, 40% (v/v) glycerol, 8% (w/v) SDS, 0.2% (w/v) bromophenol blue, 0.4 M DTT) and then proteins were 
resolved by SDS-PAGE and detected by Western blotting as follows. 
 
MGMT 
Cells were lysed with 20 mM tris HCl pH 8.5, 1 mM EDTA, 5% glycerol, 1 mM β-mercaptoethanol, 0.1 mM 
PMSF in EtOH, in presence of protease inhibitors (10 µg/ml aprotinin, 5 µg/ml leupeptin, 5 µg/ml pepstatin, 3 
µg/ml bestatin), as recently described [252]. Cell proteins were resolved by SDS-PAGE on 12% 
polyacrylamide gels and transferred onto nitrocellulose membranes. Membranes were then blocked in 5% 
milk using 0,05% PBS-Tween20, incubated for 1 hour with anti-MGMT primary antibody (1:50) and finally 
with a mouse anti-goat horseradish peroxidase-linked secondary antibody (1:2000). β-actin was used as 
loading control.  
 
Sphingosine kinases 
Cells were lysed with 20 mM HEPES pH 7.4, 50 mM NaCl,1 mM EGTA pH 8, 1% Triton X100, 5 mM β-
glicerophosphate, 2 mM sodium orthovanadate, 0.1 mM sodium pyrophosphate, 1 mM EDTA, in presence of 
protease inhibitors (2 µg/ml aprotinin, 2 µg/ml leupeptin, 2 µg/ml pepstatin). In order to evaluate SK1 
expression, cell proteins were resolved by SDS-PAGE on 10% polyacrylamide gels and transferred onto 
nitrocellulose membranes. Moreover, to evaluate SK2 expression, cell proteins were resolved by SDS-PAGE 
on 12.5% polyacrylamide gels and transferred onto PVDF membranes. Membranes were then blocked in 5% 
milk using 0.05% TBS-Tween20, incubated for 1 hour with anti-SK1 (1:500), anti-SK2 (1:3000) primary 
antibodies and then with goat anti-rabbit horseradish peroxidase-linked secondary antibody (1:500 and 1:300 
respectively). GAPDH or β-actin were used as loading control. 
 
ABCG2 
Cells were lysed with 10 mM tris HCl pH 7.4, 0.25 M sucrose in presence of protease inhibitors (1 µg/ml 
aprotinin, 1 µg/ml leupeptin, 1 µg/ml pepstatin). Cell proteins were resolved by SDS-PAGE on 10% 
polyacrylamide gels and transferred onto nitrocellulose membranes. Membranes were then blocked in 10% 
milk using 0.1% TBS-Tween20, incubated overnight with anti-ABCG2 primary antibody (1:1000) and finally 
with goat anti-mouse horseradish peroxidase-linked secondary antibody (1:2000). β-actin was used as 
loading control. 
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ABCA1 
Cells were lysed with 10 mM tris HCl pH 7.4, 1 mM MgCl2, 1% NP-40, 0.5% Na-deoxycholate, 5 mM EDTA 
in presence of protease inhibitors (1 µg/ml aprotinin, 0.5 µg/ml leupeptin, 1 µg/ml pepstatin). Cell proteins 
were resolved by SDS-PAGE on 7.5% polyacrylamide gels and transferred onto PVDF membranes. 
Membranes were then blocked in 5% milk using 0.1% TBS-Tween20, incubated for 2 hours with anti-ABCA1 
primary antibody (1:1000) and then with goat anti-mouse horseradish peroxidase-linked secondary antibody 
(1:1000). β-actin was used as loading control. 
 
ABCC1 
Cells were lysed with 50 mM HEPES pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 100 mM NaF, 1 mM EGTA pH 8, 
10% glycerol, 1% Triton X100, 0.2 mM sodium orthovanadate, 10 mM sodium pyrophosphate in presence of 
protease inhibitors (2 µg/ml aprotinin, 2 µg/ml leupeptin, 5 µg/ml pepstatin). Cell proteins were resolved by 
SDS-PAGE on 7.5% polyacrylamide gels and transferred onto PVDF membranes. Membranes were then 
blocked in 5% milk using 0.2% TBS-Tween20, incubated for 1 hour with anti-ABCC1 primary antibody 
(1:250) and finally with goat anti-mouse horseradish peroxidase-linked secondary antibody (1:1000). β-actin 
was used as loading control. 
 
In all cases bound antibodies were visualized by ECL (SuperSignal West Pico or West Femto Maximum 
Sensitivity Chemioluminescent Substrate), and membranes were exposed to Kodak Biomax films. 
 
 
4.6 Metabolic studies 
Pulse experiments with [3H]-DHSph. T98G and TMZ-R cells were plated on 35 mm dishes in cell culture 
medium at 3 x 105 cells/dish. Cells were fed with 1 µM [3H]-DHSph (60 Ci/mmol) in growth medium for 2 
hours and then incubated with 0.5 mM TMZ. After 16 and 38 hours, adherent and floating cells were 
collected and submitted to lipid extraction, partitioning and methanolysis, as described below. 
 
Pulse experiments with [3H]-Sph. U87-MG and GSCs cells were plated on 35 mm dishes in cell culture 
medium at 5 x 105 cells/dish. At the time of the experiment, the medium was gently removed and cells were 
then pulsed with 20 nM [3H]-Sph (0.4 µCi/ml), for the indicated periods of time, in presence of growth 
medium containing 10 mM sodium glycerophosphate, 5 mM sodium fluoride, 0.5 mM deoxipyridoxine, and 
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0.5% BSA or 10% FCS, to trap released S1P [253]. At the end of the pulse cells and media were collected 
and processed as described below. 
 
Extraction and partitioning of intracellular lipids    
At the end of the pulse period, cells were harvested and total lipids were extracted at 4°C with 
chloroform/methanol 2:1 (v/v) as previously reported [254]. In particular, after mixing, samples were 
centrifuged at 10000 x g for 15 minutes at 4°C. The supernatant was collected and the precipitated was re-
extracted with 200 µl chloroform/methanol 2:1 (v/v), mixed and centrifuged. The second supernatant 
obtained was added to the first one. The two supernatants combined represent the total lipid extract (ELT). 
An aliquot of the ELT was counted for radioactivity by liquid scintillation. Pellets obtained after lipid 
extraction, containing cellular proteins, were dried a under nitrogen stream and digested over night with 50 µl 
1N NaOH at RT. Digestion was stopped with 450 µl distilled water. Aliquots were analyzed for protein 
content with the Lowry based assay. 
ELT was then partitioned adding 260 µl of 0.1 M NH4OH. After vigorous and repeated shaking, phases were 
separated by centrifugation at 8500 x g for 5 minutes at 4°C. At the end of the centrifugation a biphasic 
solution was obtained, composed of an upper aqueous phase (FA), containing the more polar intracellular 
lipids (S1P and gangliosides) and a lower organic phase (FO), containing the more apolar intracellular lipids 
(Cer, GlcCer , LacCer, Sph, and SM). Both FA and FO were evaporated under a nitrogen stream. FA was 
dissolved in chloroform/methanol/concentrated HCl 100:100:1 (v/v/v), counted for radioactivity by liquid 
scintillation and then analysed by HPTLC (as described below). Meanwhile FO was submitted to mild 
alkaline methanolysis. 
 
Mild alkaline methanolysis of the FO  
Since the FO obtained by ELT contains not only tritated sphingolipidic metabolites but also 
glycerophospholipids, it was submitted to a mild alkaline methanolysis to remove glycerophospholipids [254]. 
To this end, FO previously dried under nitrogen stream, was dissolved in 50 µl chloroform and then 50 µl of 
0.2 N KOH in methanol were added. Samples were mixed and incubated 1 hour at 37°C under constant 
stirring. The reaction was stopped by neutralization with 60 µl of 0.2 N HCl in methanol. In order to reach the 
final chloroform/methanol ratio 2:1 (v/v), 90 µl methanol and 350 µl chloroform were added. After mixing, 
phases were separated by the addition of 95 µl water and centrifugation at 8500 x g for 5 minutes at 4°C. 
The upper aqueous phase was removed and the lower organic phase was dried under a nitrogen stream, re-
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suspended in 300 µl chloroform/methanol 2:1 (v/v), counted for radioactivity and analysed by HPTLC (as 
described below). 
 
Extraction and partitioning of extracellular S1P 
Extracellular S1P was extracted from pulse medium and purified, as described elsewhere [174,175]. In 
particular, a two-step partitioning was performed, at first in alkaline conditions and then a back extraction of 
the aqueous phase obtained was carried out in acidic conditions according to Yatomi et al. (1995) [255] and 
Edsall and Spiegel (1999) [256] with some modifications. Briefly, 400 µl of medium were added to 750 µl of 
cold chloroform/methanol/concentrated HCl 100:200:1 (v/v/v). Samples were mixed at 4°C and phases were 
separated by the addition of 500 µl of chloroform and 130 µl of 3.5 N NH4OH. After centrifugation at 10000 x 
g for 5 minutes at 4°C, the upper aqueous phase, containing volatile metabolites and extracellular S1P, was 
further partitioned adding 750 µl of chloroform and 40µl of 37% HCl. After mixing and centrifugation as 
above, the acidic organic phase obtained, containing extracellular S1P, was evaporated under nitrogen 
stream, resuspended in choloform/methanol/concentrated HCl 100:100:1 (v/v/v), and analysed by HPTLC. It 
has been previously demonstrated that in this condition about 90% of S1P is recovered [174]. Meanwhile the 
alkaline acqueous phase obtained was analyzed to determine [3H]-S1P degradation. 
 
Determination of S1P degradation 
The tritiated water produced during [3H]-S1P degradation was determined purifying, by fractional distillation, 
the alkaline acqueous phase obtained during the partitioning of the culture medium [254]. An aliquot of this 
aqueous phase was diluted in water and submitted to distillation. The fraction distilling at 100°C was 
collected and counted for radioactivity by liquid scintillation. It has been previously demonstrated that no loss 
of tritium by evaporation occurred under the experimental conditions used [174]. 
 
Separation and identification of [3H]-sphingolipids by HPTLC 
After extraction and partitioning, the fractions containing [3H]-sphingolipids were submitted to high 
performance thin layer chromatography (HPTLC) on silica gel plates, using an opportune solvent system in a 
chromatographic chamber.  
Sphingolipids contained in the cellular FO of cells pulsed with [3H]-DHSph or [3H]-Sph, were separated using 
as solvent system chloroform/methanol/acetic acid (190:9:1, v/v/v) or chloroform/methanol/water (110:40:6, 
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v/v/v), respectively; a standard mix composed of tritiated Cer, GlcCer , LacCer, Sph, and SM was 
chromatographed on the same plate and used as internal standard. 
The fractions containing cellular and extracellular S1P were separated using n-butanol/acetic acid/water 
(3:1:1, v/v/v) as solvent system. Standard [3H]-S1P was chromatographed on the same plate and used as 
internal standard.  
At the end of the chromatography, HPTLC plates were dried and submitted to digital autoradiography (Beta-
Imager 2000, Biospace, Paris, FR). Sphingolipids were quantified by the beta vision analysis software 
(Biospace, Paris, FR).  
 
 
4.7 Sphingosine kinase activity  
SKs activity was evaluated both intracellularly and in cell-conditioned medium in order to assess whether 
GSCs released these enzymes in the extracellular milieu. To this end, U-SC (5 x 105 cells/dish) were 
incubated at 37°C in fresh culture medium for different periods of time (30, 60 minutes and 24 hours). 
Subsequently cells and media were collected in order to evaluate SKs activity. 
Cells were harvested in SK buffer (20 mM Tris-HCl pH 7.4 containing 1 mM EDTA, 0.5 mM deoxypiridoxine, 
15 mM NaF, 1 mM β-mercaptoethanol, 1 mM sodium orthovanadate, 40 mM sodium glycerophosphate, 10% 
glycerol and protease inhibitors) and disrupted by freeze-thawing. Protein concentration was determined 
through the Lowry based method. 
SKs activity was assayed using experimental conditions known to selectively favour SK1 or SK2 activity with 
minor modifications [152,154,167]. Briefly, the reaction mixture (final volume, 100 µL) contained: cell 
homogenate (15-30 µg), 50 µM D-erytrhro-sphingosine as BSA-complex, 1 mM [γ-32P]ATP, 5 mM MgCl2 and 
SK buffer supplemented with either 0.5% Triton X 100 to asses SK1 activity, or 200 mM KCl to asses SK2 
activity. The mixture was incubated at 37°C for 30 minutes. 
 
Media were collected and concentrated by centrifugation at 5110 x g for 1 hour at 4°C. SKs activity was 
assayed preparing the reaction mixture (final volume, 100 µL) containing: concentrated medium (25-50µl), 25 
µM D-erytrhro-sphingosine as BSA-complex, 0.5 mM [γ-32P]ATP, 5 mM MgCl2 and SK buffer supplemented 
with either 0.5% Triton X100 or 200 mM KCl in order to asses SK1 or SK2 activity respectively. The mixture 
was incubated at 37°C for 30 minutes. 
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Both cells and media reactions were terminated and lipids were extracted, as previously described [174,239]. 
In particular reactions were stopped by the addition of 10 µL 1 M HCl followed by 400 µL 
chloroform/methanol/HCl (100:200:1, v/v/v). After mixing, 120 µL of chloroform and 120 µL of 2 M KCl were 
added and phases separated by centrifugation at 1000 x g for 10 minutes at RT. A biphasic solution was 
obtained, composed of an upper aqueous phase (FA) rich in labeled ATP and a lower organic phase (FO), 
containing labelled lipids. The FO was recovered and transferred into a test tube, evaporated to dryness 
under a stream of nitrogen and then dissolved in chloroform/methanol/concentrated HCl 100:100:1 (v/v/v). 
Labelled lipids in the organic phase were then resolved by HPTLC on silica gel plates using 1-
butanol/methanol/acetic acid/water 8:2:1:2 (v/v/v/v) as solvent system. At the end of the chromatography, 
HPTLC plates were dried and labelled lipids visualized using autoradiography by overnight exposure to 
Kodak Biomax films. The radioactive spots corresponding to S1P were scraped from the plates and counted 
for radioactivity by liquid scintillation. Background values were determined in negative controls in which 
sphingosine was not added to the reaction mixture. 
 
 
4.8 Protein assays 
The determination of the protein content was performed using the Bradford/Comassie [257] method or the 
Lowry assay [258]. In both cases bovine serum albumin (BSA) was used as standard and a calibration curve 
was set up using increasing amounts of BSA. The protein content was obtained by spectrophotometric 
reading at 595 nm for the Bradford method and 750nm for the Lowry assay. 
 
 
4.9 Statistical analysis 
Results are expressed as means ± SD or SEM for at least three independent experiments. The statistical 
significance of the data was determined by the Student’s t-test. Significant differences were accepted at least 
p < 0.05. Data were analyzed using StatMate software, version 4.0 (GraphPad). 
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RESULTS 
 
 
5.1 Effect of TMZ on T98G cell viability 
To examine the antitumour effect of TMZ on malignant glioma cells, we treated T98G cells with TMZ at 
concentrations ranging from 0.1 mM to 1.5 mM in complete medium. We found that this alkylating agent 
inhibits cell viability in a dose-dependent manner, and this effect increases with prolonged drug exposure 
(data not shown). After 72 hours of treatment with TMZ, the drug sensitivity parameters D37 and LD10 
(indicating the TMZ doses required to reduce cell viability to 37% and 10% respectively [259]) were 
calculated. In particular, in T98G glioblastoma cells D37 was 285 µM and LD10 was 814 µM (Table 1). 
As a model of drug-induced resistance in glioma cells, we used the TMZ-resistant (TMZ-R) variant previously 
obtained in our laboratory from T98G cells by selection with increasing drug concentrations. As shown in 
Table 1, the resistance parameters D37 and LD10 were increased in the TMZ-R variant, the corresponding 
resistance factors being more than five-fold higher than those of the parental T98G [252].  
 
 
 
Table 1. TMZ cytotoxicity in T98G cells and T98G TMZ-resistant variant. T98G and TMZ-resistant cells were exposed to 
increasing doses of TMZ (0.1-1.5 mM). Cell viability was evaluated after 72 hours by MTT assay. The drug sensitivity 
parameters D37, LD10 and the corresponding resistance factor are shown. 
 
 
5.2 Expression of the TMZ-resistance marker MGMT in T98G and TMZ-resistant cells. 
One of the best characterized mechanisms of resistance to the alkylating agent TMZ is the increased 
expression of the DNA repair protein MGMT [37], which is able to remove the methyl groups added to the 
DNA by alkylating agents. Therefore, the role of this enzyme in TMZ sensitivity was evaluated. To this 
purpose, MGMT protein level was assessed both in T98G and TMZ-R cells by Western blot analyses. As 
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shown in Figure 13, our results demonstrated that MGMT expression levels were markedly higher in TMZ-R 
than in T98G cells, indicating that MGMT has a role in TMZ-resistance in this cell line.  
 
 
 
Figure 13. Expression of MGMT protein. T98G and TMZ-resistant cells were lysed and aliquots containing 20 µg of 
proteins were analyzed by immunoblotting assays with anti-MGMT and anti-GAPDH antibodies. The immunoblottings 
shown are representative of one out of three identical experiments performed.  
 
 
5.3 Effect of TMZ on the regulation of ceramide levels in T98G cells 
An increasing amount of evidence indicates that ceramide plays an important role as a tumour suppressor 
lipid, is able to induce antiproliferative and apoptotic responses, and acts as a major player in the 
mechanism of action of many chemotherapeutic drugs [107,260,261]. On this premise, we investigated 
whether TMZ treatment was involved in ceramide formation. To this purpose, we labelled cells for 2 hours 
with [3H]-DHSph, as ceramide precursor. We then evaluated ceramide content after 16 hours of TMZ 
treatment, when no significant variation in the number of adherent cells was measurable, and later on, at 38 
hours, when adherent cells were reduced and numerous cells floating in the medium were evident after 
treatment (Fig. 14A and 14B).  
 64 
 
 
Figure 14. TMZ induces cell death and increases ceramide level in T98G cells. Cells were incubated with 1 µM [3H]-
DHSph (60 Ci/mmol) for 2 hours, and then in the absence (-TMZ) or presence of 0.5 mM TMZ (+TMZ) for 16 or 38 hours. 
At the end, adherent (A) and floating cells (B) were counted and resulted trypan blue negative and positive, respectively. 
At the end of incubation, both adherent (C) and floating cells (D) were also processed and analyzed to evaluate the 
radioactivity incorporated into ceramide, as described in “Materials and methods”. Ceramide is expressed as the 
percentage of radioactivity incorporated into the lipid extract. Data are the mean ± SD of three independent experiments. 
Asterisks represent statistical significance determined by Student’s t test (** p < 0.01, ***p < 0.001 vs un-treated cells). 
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Trypan blue analyses revealed that the large majority (>98%) of adherent cells were vital, and that floating 
ones were trypan blue positive, i.e. dead. We therefore analysed both adherent and floating cells 
(representing vital and dead cells, respectively) for their ceramide content. At both times of treatment, the 
cell-incorporated radioactivity (as sum of adherent and floating cell-associated radioactivity) was similar in 
control and TMZ-treated cells (data not shown), thus indicating that the drug treatment did not affect DHSph 
incorporation into the cells. The results of the ceramide content in adherent cells revealed a time-dependent 
increase in TMZ-treated cells (Fig. 14C). Interestingly, the ceramide level in drug-treated floating cells was 
markedly higher (about two-fold) than in control ones, independently of the time (Fig. 14D).  
Notably, and in contrast to what it occurs in T98G, in TMZ-R cells, no significant variation in the ceramide 
level was found after treatment with TMZ (up to 1 mM) (data not shown) [252]. 
 
 
5.4 Effect of ceramide on T98G cell viability 
Prompted by these findings, we evaluated the effect of ceramide on cell fate. To this purpose, T98G cells 
were exposed for 24 hours to different concentrations of cell-permeable ceramide analogues and cell death 
was determined. As shown in Figure 15A, exposure of T98G to increasing doses of C2-ceramide and C6-
ceramide resulted in a dose-dependent effect on cell death. Of relevance, as shown in Figure 15B, this 
cytotoxic effect was mimicked by a long-chain ceramide derived from bovine brain sphingomyelin, containing 
18:0, 24:1, and 24:0 as major fatty acid species [262]. As expected on the basis of their cell permeability, the 
potency of the cytotoxic effect of the different ceramides was inversely related to the length of their N-acyl 
chain (Fig. 15B) [252].  
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Figure 15. Ceramides induce cell toxicity in T98G glioblastoma cells. T98G cells were exposed to different doses of C2- 
and C6-ceramide (A), and 100 µM C2-ceramide, C6-ceramide or long-chain ceramides (B). After 24 hours, cell viability 
was assessed by MTT assay. Results are expressed as percentage of cell viability with respect to un-treated cells 
(regarded as 100%). Data are mean ± SD of three-five independent experiments. Asterisks represent statistical 
significance determined by Student’s t test (** p < 0.01, ***p < 0.001 vs un-treated cells). 
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5.5 Isolation and characterization of GSCs 
Stimulated by these results, we decided to evaluate the role of sphingolipids also in GSCs, a cell 
subpopulation within the tumour involved in the aberrant expansion and therapy resistance properties of 
glioblastomas [50,51]. To this purpose we isolated GSCs from the human U87-MG glioblastoma multiforme 
cell line, known to be particularly enriched with cancer stem cells [263]. 
GSCs were isolated from U87-MG using a selective growth medium, which promotes the proliferation of the 
stem cell component only (U-SC). The isolation process usually lasts one month, during which, in selective 
serum-free conditions, differentiating/differentiated cells rapidly die, while the stem cell component proliferate 
forming compact cell clusters floating in suspension, called “neurospheres”. Importantly, only a fraction of the 
initial neurospheres, ranging from 10 to 50% of the total cells, retains stem cell features, while the remainder 
of the cells undergo spontaneous differentiation [250]. In fact, an initial neurosphere is a mixture of stem 
cells, differentiating progenitors, and even terminally differentiated glioblastoma cells. This is the reason why, 
in order to obtain in the progressive enrichment and stable expansion of U-SC in culture, during the isolation 
process every week neurospheres were subcultured by harvesting, followed by dissociation and re-plating 
under the same growth conditions. 
Images acquired by phase-contrast microscopy (Fig. 16A), showed obvious morphological differences 
between the two cell types. U87-MG cells grew adherent to the surface of the growth support, with a 
fibroblastoid-like morphology characterized by the formation of numerous cytoplasmic extensions (Fig. 16A). 
Conversely, U-SC grew in suspension in the culture medium forming typical neurosphere structures (Fig. 
16A), composed of 100-200 cells.  
It has been reported that brain tumour-derived cancer stem cells express high levels of the membrane 
glycoprotein CD133 and the cytoskeleton protein nestin [54,55]. In order to assess if the population of cells 
obtained by selective isolation was actually enriched in stem cells, the expression of stemness markers was 
evaluated by a Real-Time PCR assay in both U87-MG and U-SC cells. Our results (Fig. 16B) showed that U-
SC presented a 5.3- and 9.5-fold increase in CD133 and nestin expression respectively, compared to U87-
MG. Thus U-SC we obtained by selective isolation were characterized by stem cell typical morphology and 
by increased expression of stemness markers, demonstrating that U-SC are representative of GSCs 
population. 
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Figure 16. Characterization of GSCs derived from U87-MG. (A) Representative images of U87-MG and U-SC 
morphology. Images were viewed on a contrast phase microscope and digital images were acquired (magnification 10X, 
Scale bar 100 µm). (B) Relative expression of CD133 and nestin, assessed by Real-Time PCR. Data were normalized to 
GAPDH expression (used as endogenous control) and U87-MG were used as calibrator. Results are shown as fold-
change relative to marker expression in U87-MG, sets arbitrarily to 1. Values are mean ± SEM of three independent 
experiments. Asterisks represent statistical significance determined by Student’s t test (** p < 0.01 U-SC cells vs U87-
MG cells). 
 
As additional in vitro model for GSCs, we exploited L0627, previously isolated from a post-surgery specimen 
of primary human glioblastoma multiforme. These GSCs reproduce the genotypic and phenotypic 
characteristics of glioblastomas more faithfully than standard glioma cell lines [48,264]. L0627 grew in 
suspension in the culture medium and efficiently formed neurospheres (Fig. 17A). Moreover, these cells 
were characterized by the high expression levels of putative cancer stem cell markers (such as CD133 and 
the adhesion molecule CD15) (Fig. 17B) and by self-renewal, multipotency and tumorigenicity, as previously 
described [48,265]. In particular, these cells, similarly to the normal neural stem cell counterpart, emerged as 
multipotent, thus able to simultaneously generate cells displaying antigenic reactivity for neuronal, astroglial 
and oligodendroglial markers in culture. More importantly, these cells were described as tumour-founding 
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cells, able to establish tumours that closely resemble the main histologic, cytologic and architectural features 
of the human disease, even when challenged through serial transplantation. 
 
 
 
Figure 17. Characterization of GSCs derived from primary culture of human glioblastoma multiforme. (A) Representative 
image of L0627 morphology viewed on a contrast phase microscope (magnification 10X, Scale bar 100 µm). (B) CD133 
and CD15 expression was assessed by flow cytometry analyses. 
 
 
5.6 Effect of TMZ on U87-MG and GSCs viability 
In order to analyze cell survival properties, increasing concentrations of the alkylating agent TMZ (ranging 
from 25 to 200 µM) were used to treat U87-MG, U-SC and L0627. After 48 hours of treatment the cytotoxic 
effect on cells was evaluated. Images of cells obtained by phase contrast microscopy show the morphologic 
effects of treatment with 100 µM TMZ for 48 hours: many of U87-MG cells were found dead in suspension, 
while those still adherent to the growth surface were strongly suffering, since characterized by a decrease of 
cell size and by the loss of normal fibroblastoid-like morphology (Fig. 18A); in contrast, U-SC and L0627 (Fig. 
18A-B), under the same experimental conditions, maintained unchanged their morphological characteristics 
with the typical formation of neurospheres. 
These morphologic data are supported by the analysis of cell viability by MTT assay. The results obtained 
show that in U87-MG cells the treatment with TMZ for 48 hours decreased cell viability in a dose-dependent 
manner. Indeed the treatment with TMZ 100 µM was associated with a cell survival of 60%, meanwhile the 
dose 200 µM caused more than 50% of cell death (Fig. 18C). Conversely treatment with TMZ at all doses 
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considered did not cause significant alterations in U-SC vitality (Fig. 18C). Also L0627 viability did not 
significantly change after 48 hours of treatment with TMZ at doses 25-100 µM. The highest TMZ 
concentration (200 µM) was only partial effective on L0627, indeed about the 70% of cells were still alive 
(Fig. 18D). Altogether these results demonstrated that at doses that were cytotoxic in U87-MG cells, TMZ 
was uneffective on U87-derived GSCs viability. Moreover, TMZ had a limited effect on L0627 survival only at 
the highest dose administrated.  
 
 
 
Figure 18. Effect of TMZ on U87-MG and GSCs viability. Representative images of (A) U87-MG, U-SC and (B) L0627 
morphology after 48 hours of treatment with vehicle (-TMZ; 0.1% DMSO) or 100 µM TMZ (+TMZ). Images were viewed 
on a phase contrast microscope and digital images were acquired (magnification 10X, Scale bar 100 µm). U87-MG, U-
SC (C) and L0627 (D) were exposed to different doses of TMZ (25-200 µM) or vehicle. Cell viability was assessed after 
48 hours of treatment by MTT assay. Results are expressed as percentage of cell viability with respect to vehicle-treated 
cells (100%). Data are mean ± SEM of three independent experiments. Asterisks represent statistical significance 
determined by Student’s t test (* p < 0.05 and ** p < 0.01 vs vehicle-treated cells).  
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5.7 Expression of the TMZ-resistance marker MGMT in U87-MG and GSCs 
The DNA repair enzyme MGMT is expressed in most of human gliomas, its levels being directly related to 
tumour resistance to alkylating drugs [37]. Therefore immunoblotting assays were performed in U87-MG, U-
SC and L0627 in order to evaluate MGMT protein levels. As shown in Figure 19, MGMT (21 kDa) was not 
expressed not only in U87-MG, but surprisingly also in U-SC and L0627.  
 
 
 
Figure 19. Expression of MGMT protein. U87-MG, U-SC and L0627 were lysed and aliquots containing 60 µg of proteins 
were analyzed by immunoblotting assays with anti-MGMT and anti-β-actin antibodies. Lysates of T98G glioblastoma cell 
line were used as positive control. The immunoblottings shown are representative of one out of three similar 
experiments.  
 
 
 72 
5.8 Expression of SK in U87-MG and GSCs 
Since data from our laboratory supported a role for S1P in TMZ resistance, we evaluated the expression of 
the two known isoforms of the enzyme sphingosine kinase (SK1 and SK2), responsible for S1P synthesis, in 
U87-MG, U-SC and L0627 cells. As shown in Figure 20, results obtained by immunoblotting assays 
demonstrated that U87-MG and the two GSCs models expressed both SK1 and SK2. 
 
 
 
Figure 20. U87-MG, U-SC and L0627 express both SK1 and SK2. Cell lysate aliquots containing 40 µg of proteins were 
analyzed by immunoblotting with anti-SK1 and anti-GAPDH antibodies (A) or anti-SK2 and anti-β-actin antibodies (B). 
The immunoblottings shown are representative of one out of three similar experiments.
 
 
 
5.9 S1P biosynthesis and fates in U87-MG and GSCs 
In order to evaluate S1P production efficiency and its metabolic fate, short time pulse experiments were 
performed in U87-MG and both GSCs by administering to cells [3H]-Sph, which is efficiently internalized by 
cells, as S1P precursor. As shown in Figure 21A, the incorporated radioactivity increased in a time-
dependent manner and was similar in all cell models. Furthermore, residual intracellular [3H]-Sph 
represented about only the 3% of the incorporated radioactivity, suggesting that all cells are able to rapidly 
metabolize sphingosine (Fig. 21A). 
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Figure 21. [3H]-Sph metabolism in U87-MG and GSCs. U87-MG, U-SC and L0627 were pulsed with 20 nM [3H]-Sph (0.4 
µCi/ml) for the indicated periods of time. At the end of incubation, cells and media were processed and analyzed as 
described in “Materials and methods”. In panel A incorporated radioactivity and intracellular unmetabolized [3H]-Sph are 
shown. Panel B displays the radioactivity associated to the process of sphingosine N-acylation. Panel C shows the 
radioactivity associated to the process of sphingosine phosphorylation. All values are mean ± SD of at least three 
independent experiments.  
 
Of note, in all cell models and at all investigated times, most of the incorporated [3H]-Sph (about 80%) was 
used in the N-acylation process, that is in the production of ceramide and its use for the synthesis of complex 
sphingolipids (glycosphingolipids and SM). Figure 21B shows that in all cell models the radioactivity 
representing sphingosine N-acylation process increased in a time dependent manner. In particular, [3H]-Cer 
represented the bulk of Sph N-acylation-associated radioactivity and increased over pulse time in U87-MG 
and L0627, whereas it showed no significant variations in U-SC. Furthermore all cells were characterized by 
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a time dependent increase in the levels of ceramide metabolism products: [3H]-SM, [3H]-GlcCer and [3H]-
LacCer. Of relevance, at all considered experimental times, [3H]-Cer levels were found higher in L0627 than 
in U-SC; meanwhile, the radioactivity associated with complex sphingolipids was lower in L0627 than in U-
SC, suggesting that in U-SC ceramide metabolism is faster and more efficient with respect to L0627.  
 
We then focused on the sphingosine phosphorylation process which can be measured on the basis of S1P 
production and degradation. Figure 21C shows that in all cell models the radioactivity representing 
sphingosine phosphorylation increased over pulse time. [3H]-S1P degradation was measured as tritiated 
water. In fact, since [3H]-S1P carries the radioactivity at the level of the C3, its degradation by S1P lyase 
produces unlabeled ethanolamine phosphate and [3H]-hexadecenal. With further dehydrogenation, the 
radioactive fatty aldehyde loses tritium with the consequent formation of tritiated water [266]. Interestingly, at 
all investigated times, tritiated water represented the bulk of Sph phosphorylation-associated radioactivity 
and raised with the increase of the pulse times (Fig. 21C) suggesting that U87-MG and both GSCs are able 
to efficiently synthesize and degrade S1P. Moreover, the radioactivity associated to S1P production had a 
similar trend in all cell models and represented about the 35% of the sphingosine phosphorylation process at 
all times considered (Fig. 21C). 
Since astrocytes, cerebellar granule cells and glioma cells are able to release S1P in the extracellular milieu 
[174,175,237,239], we analyzed both cells and culture media in order to evaluate [3H]-S1P distribution in 
U87-MG and GSCs. 
Concerning U87-MG, the radioactivity associated with intracellular S1P increased in a time-dependent 
manner, as shown in Figure 22A. Additionally, a small amount of S1P, corresponding to the 3% of the 
radioactivity associated to sphingosine phosphorylation, was detected extracellularly at both 30 and 60 
minutes (Fig. 22B).  
Data obtained in U-SC show that the radioactivity associated with intracellular S1P decreased over pulse 
time (Fig. 22A). Meanwhile, in L0627, intracellular S1P radioactivity increased at 30 minutes of pulse and 
remained constant at 60 minutes (Fig. 22A). Furthermore, in both GSCs models the radioactivity associated 
with extracellular S1P increased with the pulse time (Fig. 22B). Intriguingly, in U-SC extracellular [3H]-S1P 
levels triplicated at 60 minutes with respect to 5 minutes of pulse. Similarly, in L0627 the radioactivity 
associated to extracellular S1P increased more than twice at 60 minutes with respect to 5 minutes of pulse. 
Of note, at all experimental times considered, tritiated water and [3H]-S1P levels were lower in L0627 than in 
U-SC, suggesting that U-SC are able to phosphorylate Sph more quickly and efficiently than L0627. 
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Figure 22. Intracellular and extracellular [3H]-S1P in U87-MG and GSCs. U87-MG, U-SC and L0627 were pulsed with 20 
nM [3H]-Sph (0.4 µCi/ml) for the indicated periods of time. At the end of incubation, cells and media were processed and 
analyzed as described in “Materials and methods”. The radioactivity incorporated into intracellular (panel A) and 
extracellular S1P (panel B) is shown. All data are expressed as nCi/dish. All values are mean ± SD of at least three 
independent experiments.  
 
Comparing results obtained in U87-MG and GSCs, we showed that in the former the radioactivity associated 
with intracellular S1P was at least 2-fold higher than in the latter. In contrast, the radioactivity associated with 
extracellular S1P in U87-MG was from 3 to 6 times lower with respect to GSCs. These results demonstrated 
that, in conditions of similar radioactivity incorporation, the extracellular/intracellular S1P ratio was much 
higher in GSCs than in U87-MG (Fig. 23A). In particular, both GSCs showed a ratio of about 1 which was at 
least 10 times higher than that in U87-MG.  
Importantly, S1P detection in GSCs medium was not accompanied by LDH release (data not shown), 
suggesting that the presence of extracellular S1P was not a consequence of cell membrane rupture. 
Furthermore, these differences in extracelluar [3H]-S1P levels between U87-MG and GSCs resulted also in a  
ceramide-extracellular S1P ratio lower in GSCs than in U87-MG. In particular this ratio was from 6 to 8 times 
lower in U-SC with respect to U87-MG (Fig. 23B). Moreover, despite in L0627 [3H]-Cer intracellular levels 
were about 2 times higher than in U87-MG, the relevant amount of [3H]-S1P found in L0627 medium led to a 
ceramide-extracellular S1P ratio which was significantly lower (more than 1.5 fold) in L0627 than in U87-MG 
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(Fig. 23B). According to the “sphingolipid rheostat” model [111], we hypothesized that this different ratio 
could promote GSC survival observed after TMZ treatment. Interestingly, this ratio is higher in L0627 with 
respect to U-SC, leading us to speculate that this could be the reason why the highest dose of TMZ used 
(200µM) had a partial effect on L0627 and no effect on U-SC viability.  
 
 
 
Figure 23. Extracellular S1P-intracellular S1P and Cer-Extracellular S1P ratios in U87-MG and GSCs. U87-MG and both 
GSCs were pulsed with 20 nM [3H]-Sph (0.4 µCi/ml) for 30 or 60 minutes. At the end of incubation, cells and media were 
processed and analyzed as described in “Materials and methods”. Histograms represent the ratio between extracellular 
and intracellular S1P-associated radioactivity (A) and the ratio between ceramide and extracellular S1P-associated 
radioactivity (B). Data are the mean ± SD of at least three independent experiments. 
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5.10 Analysis of SK activity in U-SC and in their culture medium 
We then hypothesized that the high amount of S1P retrieved in GSCs medium could be consequent to 
sphingosine kinase secretion in the extracellular milieu, as it occurs in some cell types [167-169]. On this 
base, we performed enzyme activity assays of the two sphingosine kinase recognized isoforms (SK1-SK2) 
on U-SC and their medium, using experimental conditions able to detect also low SK activity. Our results 
demonstrated the presence of the two SK isoforms inside the cells and the absence of these two enzymes in 
the culture medium (Fig. 24). These data excluded our hypothesis, suggesting that a very efficient transport 
mechanism is involved in S1P export from GSCs.  
 
 
 
Figure 24. SK activity in U-SC and in their culture medium. U-SC were incubated at 37°C in fresh culture medium for 24 
hours. Subsequently cells and media were collected in order to evaluate SKs activity as described in “Materials and 
methods”. Enzyme activity was measured using sphingosine and [γ-32P]ATP as substrates, under buffer conditions 
favouring SK1 or SK2 activity. Data are the mean ± SD of at least three independent experiments. 
 
 
5.11 Expression of ABCG2, ABCC1 and ABCA1 membrane transporters in U87-MG and GSCs 
The mechanism of S1P transport across the plasma membrane is still unclear. Increasing evidence supports 
that different subfamilies of ATP binding cassette (ABC) transporters contribute to sphingolipid passage 
across the membrane. In particular ABCG2, ABCA1 and ABCC1 were found involved in the S1P export to 
the extracellular milieu [173,178,180]. On this base we then analyzed, in U87-MG and both GSCs, the 
expression of these three ABC transporters. 
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Data obtained through immunoblotting assays demonstrated that ABCG2 is expressed in U87-MG cells, 
meanwhile in U-SC it is expressed at very low levels, at the limit of method-sensitivity, and it is was not found 
to be expressed in L0627 (Fig. 25A). Furthermore, no band for ABCC1 expression was detected either in 
U87-MG or in GSCs (Fig. 25C). Only ABCA1 resulted present in GSCs, and it appeared to be much more 
expressed in U87-MG than in both GSCs (Fig. 25B).  
These findings stimulated us to analyze the possible involvement of this transporter in the extracellular 
release of S1P by GSCs. Further analyses revealed that ABCA1 inhibition, through the sulfonylurea 
derivative glyburide, caused no variations in L0627 ability to release S1P (data not shown). 
 
 
 
Figure 25. Expression of ABCG2, ABCC1 and ABCA1 membrane transporters in U87-MG and GSCs. Cell lysate 
aliquots containing 40 µg of proteins were analyzed by immunoblotting with anti-ABCG2 (A), anti-ABCA1 (B) or anti-
ABCC1 (C) antibodies. β-actin levels were used as protein-loading control. Lysates of T98G glioblastoma cell line were 
used as positive control for ABCC1 expression.The immunoblottings shown are representative of one out of three 
identical experiments performed. 
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5.12 S1P biosynthesis and fates in L0627 treated with TMZ 
The evidence that GSCs are resistant to TMZ and their ability to release S1P in the extracellular 
microenvironment, stimulated us to analyze the effect of TMZ treatment on S1P biosynthesis and fates in 
GSCs. To this purpose L0627 were incubated with 100 µM TMZ for 24 hours and then pulsed with tritiated 
sphingosine for 1 hour. Total incorporated radioactivity was found similar in un-treated and treated cells (217 
nCi/dish and 207 nCi/dish, respectively). Sphingosine N-acylation and phosphorylation processes had a 
similar trend, with no significant variations, in the absence or presence of TMZ (Fig. 26A-B). We found that 
the radioactivity associated to intracellular S1P was similar in treated and untreated cells, meanwhile, 
intriguingly, extracellular [3H]-S1P levels increased by 40% in cells exposed to TMZ with respect to untreated 
cells (Fig. 26C).  
 
 
 
Figure 26. [3H]-Sph metabolism in L0627 treated with TMZ. L0627 were treated with vehicle (Ct, 0.1% DMSO) or 100 µM 
TMZ (+TMZ) for 24 hours and then pulsed with 20 nM [3H]-Sph (0.4 µCi/ml) for 60 minutes. At the end of incubation, cells 
and media were processed and analyzed as described in “Materials and methods”. Radioactivity associated to the 
processes of sphingosine N-acylation (A) and sphingosine phosphorylation (B) are shown. (C) Radioactivity incorporated 
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into intracellular and extracellular S1P is represented. All data are expressed as nCi/dish. All values are mean ± SD of at 
least three independent experiments. Asterisks represent statistical significance determined by Student’s t test (** p < 
0.01 vs vehicle-treated cells). 
 
 
5.13 Role of S1P in TMZ-induced toxicity in U87-MG 
As reported above, U87-MG were sensitive to the cytotoxic action of 50-200 µM TMZ, whereas GSCs were 
resistant to these drug concentrations. Furthermore, U87-MG cells were characterized by markedly lower 
levels of extracellular S1P with respect to those of GSCs. We then examined whether exogenous S1P 
administration might be able to modulate U87-MG cell death by counteracting the cytotoxic effect of TMZ. To 
this purpose we administered to serum-starved cells 50 µM TMZ in the absence or presence of extracellular 
S1P (200 nM) for 48 hours.  
The results obtained through MTT assay (Fig. 27), revealed that exogenously administered S1P by itself 
increased the number of viable cells by 20% with respect to control cells treated only with vehicle. 
Furthermore, the treatment with TMZ alone caused a 50% decrease in cell viability. Interestingly, exogenous 
S1P was able to reduce the cytotoxic effect of TMZ, determining a 2-fold increase in viable cell number, 
compared to cells treated only with TMZ.  
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Figure 27. Effect of exogenous S1P on TMZ-induced toxicity in U87-MG. Cells were serum-starved for 24 hours and 
then incubated in serum-free medium containing 50 µM TMZ in the absence or presence of 200 nM S1P. After 24 hours 
200 nM S1P was added again. Cell viability was assessed by MTT assay after 48 hours of treatment. Results are 
expressed as percentage of cell viability with respect to vehicle-treated cells (100%). Data are mean ± SEM of three 
independent experiments. Asterisks represent statistical significance determined by Student’s t test (** p < 0.01). 
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5.14 Role of S1P in GSCs survival properties 
Stimulated by these results, we investigated the putative role of S1P in GSCs resistance to TMZ. First of all, 
U-SC and L0627 were treated with different concentrations of TMZ (100-200 µM) in the absence or presence 
of the sphingosine kinase inhibitor SKI. After a 48 hours treatment, high doses of TMZ failed to induce cell 
death in U-SC and had only limited effects on L0627 survival. Moreover, at the administered concentration, 
the treatment with SKI alone did not significantly affect cell viability (data not shown). On the other hand, 
intriguingly, the co-treatment with SKI and TMZ dramatically decreased cell viability (Fig. 28). In particular, in 
U-SC treated with 100 µM TMZ in the presence of SKI, cell viability was decreased by 70%, compared to 
cells treated only with TMZ (Fig. 28A). Moreover, in L0627 the same treatment induced a decrease in cell 
survival of about 90% with respect to TMZ alone (Fig. 28B). Taken together these data suggest that SKI 
makes GSCs sensible to TMZ toxicity.  
 
 
 
Figure 28. Role of S1P in GSCs survival properties. (A) U-SC and (B) L0627 were exposed to different doses of TMZ 
(100-200 µM) alone (♦) or in combination with 4 µM SKI (●). Cell viability was assessed by MTT assay after 48 hours of 
treatment. Results are expressed as percentage of cell viability with respect to vehicle-treated cells (♦) or cells treated 
with SKI alone (●) (100%). Data are mean ± SEM of at least three independent experiments. Asterisks represent 
statistical significance determined by Student’s t test (* p < 0.05 and ** p < 0.01 vs vehicle-treated cells). 
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Subsequently, in order to assess the importance of extracellular S1P in GSC TMZ resistance, we evaluated 
the effect of S1P on L0627 in the presence or not of TMZ and SKI, separately or in combination. As shown in 
Figure 29, in control cells treated only with vehicle, the administration of exogenous S1P for 48 hours by 
itself slightly increased the number of viable cells. Moreover, in the presence of TMZ, S1P was able to 
promote a 40% increase in cell survival, thus indicating that S1P enhances GSC refractoriness to TMZ. 
Remarkably, exogenous S1P was able to strongly revert the sensitizing effect of SKI on TMZ toxicity 
determining a 5-fold increase in viable cells.  
 
 
 
Figure 29. Extracellular S1P promotes GSCs resistance to TMZ. L0627 were exposed to 200 nM S1P, 100 µM TMZ, 4 
µM SKI, separately or in combination, as indicated. After 24 hours 200 nM S1P was added again. Cell viability was 
measured by MTT assay after 48 hours of treatment. Results are expressed as percentage of viable cells with respect to 
vehicle-treated cells (100%). Data are mean ± SEM of at least three independent experiments. Asterisks represent 
statistical significance determined by Student’s t test (* p < 0.05 and ** p < 0.01). 
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5.15 S1P production in GSCs isolated from two patients with a different GBM aggressive phenotype 
The GSC ability to release S1P in the extracellular microenvironment stimulated us to evaluate its possible 
involvement in determining GBM aggressiveness. To this purpose, we used GSCs isolated from two GBM 
specimens obtained from patients showing a different prognosis. One patient (PT 1) was characterized by 
the absence of mutations in p53 oncosoppressor gene; meanwhile the other patient (PT 2) presented an 
inactivating mutation of p53. Interestingly, tumour in PT 2 had a higher grade of malignancy, showing a more 
aggressive phenotype, with respect to PT 1. Indeed only PT 2 death was consecutive to the formation of an 
early relapse. 
Both GSC models were characterized by the high expression levels of the recognized cancer stem cell 
markers, CD133 and CD15 (Tab. 2).  
 
 
 
Table 2. Characterization of GSCs derived from two patients with a different GBM aggressive phenotype. CD133 and 
CD15 expression was assessed by flow cytometry analyses. 
 
We evaluated S1P production in these two GSC models pulsing cells with tritiated sphingosine for 15, 30 
minutes and 2 hours. Total incorporated radioactivity increased in a time-dependent manner and was similar 
in the two GSC models (data not shown). We found that the radioactivity associated with intracellular S1P 
remained constant in cells derived from PT 2, meanwhile it doubled at 30 minutes and remained constant at 
two hours of pulse in cells derived from PT 1 (Fig. 30A). However, intracellular [3H]-S1P levels were similar in 
the two GSCs. Furthermore, in both cases the radioactivity associated with extracellular S1P increased with 
pulse time, tripling from 30 minutes to 2 hours. Intriguingly, we found that at all the investigated times 
extracellular [3H]-S1P level was at least 4 times higher in GSCs derived from PT 2 with respect to those 
derived from PT 1 (Fig. 30B). These findings led to an extracellular/intracellular S1P ratio at least 3 times 
higher in GSCs from PT 2 than in those from PT 1 (Fig. 30C). 
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Figure 30. Intracellular and extracellular [3H]-S1P in GSCs isolated from two patients with a different GBM aggressive 
phenotype. GSCs isolated from PT 1 and PT 2 were pulsed with 20 nM [3H]-Sph (0.4 µCi/ml) for the indicated periods of 
time. At the end of incubation, cells and media were processed and analyzed as described in “Materials and methods”. 
The radioactivity incorporated into intracellular S1P (A), extracellular S1P (B) and the ratio between extracellular and 
intracellular S1P-associated radioactivity (C) are shown. All values are the mean ± SD of at least three independent 
experiments.  
 
 86 
DISCUSSION 
 
Glioblastoma multiforme is the most frequent and aggressive primary central nervous system tumour in 
humans, with one of the worst survival rates of all the human cancers [1], due to the high proliferation rate, 
the migrating and invasive properties, and, not last, the resistance to current therapeutic intervention. The 
introduction of the alkylating agent TMZ in glioblastoma therapy improved patient survival, but drug 
resistance mechanisms limit its benefits and the prognosis remains unfavorable [33]. The development of 
effective chemotherapy for gliomas is limited by a relative lack of understanding of the mechanisms of TMZ 
toxicity and chemoresistance in the tumour cells. Our study provides a contribution to this complex field.  
First, to examine the antitumour effect of TMZ on malignant glioma cells, we used the human T98G 
glioblastoma multiforme cell line as cell model. Furthermore, since the establishment of cell lines with 
induced drug resistance is an effective model to clarfy the molecular basis of anticancer drug resistance, 
TMZ-R cells from T98G cells were generated and used. Both cell models were treated with increasing 
concentrations of TMZ. Our results demonstrated that TMZ, at doses that were cytotoxic in T98G cells, had 
no significant effect on TMZ-R viability, the resistance factor being five-fold greater than that of the parental 
T98G. Therefore, the expression of the DNA repair protein MGMT, a major contributor to TMZ-resistance 
[36] was assessed. We obtained that TMZ-R cells showed a marked increase in MGMT expression levels in 
comparison to T98G cells, indicating that MGMT has a role in TMZ-resistance in this cell line [252]. 
Accumulating literature indicates that ceramide plays an important role as a tumour suppressor lipid, able to 
induce antiproliferative and apoptotic responses, and that it is a major player in the mechanism of action of 
many chemotherapeutic drugs [107,260,261]. Therefore, we examined whether ceramide production is 
involved in the mechanism of TMZ-induced toxicity. Our data demonstrated that cytotoxic doses of TMZ 
induce a significant increase in ceramide in T98G glioma cells. Of note, this increase occurs prior to 
significant evidence of cell death (i.e., variation in total viable cells), suggesting a role of ceramide as a 
mediator of cytotoxicity. Interestingly, dead cells floating in the medium after TMZ treatment, which increased 
with treatment time, exhibited relevant higher levels of ceramide than those in vital, attached cells. Thus, it 
appears that TMZ increases ceramide, and when this increase reaches a certain level, cells undergo death. 
Furthermore, we found that in TMZ-R cells the administration of high doses of TMZ (highly cytotoxic in 
sensitive cells) failed to induce variations in ceramide content, as it occurs in T98G, supporting that this drug 
is not able to induce ceramide accumulation in resistant cells [252].  
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Prompted by these results, we next investigated ceramide effect on T98G viability. Our experiments 
demonstrated that ceramide analogs and ceramide itself were able to exert a cytotoxic effect in a dose-
dependent manner.  
From this first set of data, it emerges that TMZ affects ceramide formation, enhancing its production in T98G 
glioma cells, and that ceramide by itself appears to act as pro-death mediator of the drug effects [252].  
Parallel studies in our laboratory demonstrated that both T98G and TMZ-R cells can release extracellularly 
newly synthesized S1P, the prosurvival antagonist of ceramide, and that S1P secreted by TMZ-R cells was 
significantly higher than that released by T98G cells. These findings suggest that S1P secretion in TMZ-R 
cells is functional to oppose the cytotoxic effect of ceramide and to the TMZ-resistant properties of cells. 
Stimulated by these initial results, we next evaluated the role of sphingolipid mediators in the malignant 
features of GSCs, the cell subpopulation within the tumour involved in the aberrant expansion and therapy 
resistance properties of glioblastomas [50,51]. 
To this purpose we first used GSCs isolated from the human U87-MG glioblastoma multiforme cell line, 
known to be particularly enriched with cancer stem cells (U-SC) [263] and GSCs isolated from a primary 
culture of human glioblastoma (L0627). Both cellular models efficiently formed typical neurosphere structures 
in mitogen-defined medium and expressed high levels of recognized cancer stem cell markers CD133, 
nestin and CD15.  
We found that TMZ, at doses that were cytotoxic in U87-MG cells, had no significant or only limited effect on 
GSCs viability. Of relevance, both GSCs were resistant to TMZ concentrations (100-200 µM) higher than that 
used in vivo in glioblastoma chemotherapeutic treatments. In fact, it was reported that levels of this drug in 
plasma and cerebrospinal fluid of patients range from 0.5 to 70 µM and from 0.8 to 10 µM, respectively [267]. 
These data, in agreement with previous studies in literature [50,51], indicate that both GSC models are 
resistant to TMZ, thus supporting that GSCs play a pivotal role in glioblastomas therapy resistance properties 
and malignancy. 
Notwithstanding, the expression of the DNA repair protein MGMT, a major factor responsible for TMZ 
resistance [36], was undetectable not only in U87-MG, but surprisingly also in GSCs. This finding strongly 
suggests that GSCs resistance to TMZ is due to mechanisms different from an increased MGMT expression. 
A large amount of evidence underlines the role of S1P as an important tumour-promoting lipid, favouring 
growth, invasion, and chemotherapy resistance of different cancer cells [247], including glioblastoma ones 
[235,248]. So far, little is known on the possible role of S1P as a factor modulating GSCs malignant 
properties. In the present study we provide evidence that directly supports GSCs as an important S1P 
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source in the extracellular microenvironment, which acts as an autocrine/paracrine signal contributing to the 
survival properties of GSCs. 
In particular, we first performed immunoblotting analyses, which demonstrated that U87-MG and the two 
GSCs models express both the known isoforms of sphingosine kinase (SK1 and SK2), the enzyme 
responsible for S1P biosynthesis. 
In addition, in order to evaluate the efficiency of S1P production and its metabolic fate, short time pulse 
experiments were performed in U87-MG and GSCs by administering to cells tritiated sphingosine as S1P 
precursor. The results of these experiments revealed the presence of radiolabeled S1P not only inside the 
cells, but also in the culture medium from both GSCs and U87-MG.  
Notably the intracellular [3H]-S1P levels were found much lower in GSC models than in U87-MG. On the 
other hand the extracellular [3H]-S1P levels in GSCs were significantly higher than in U87-MG. These 
differences resulted in an extracellular/intracellular S1P ratio at least 10 times higher in GSCs compared to 
U87-MG. Furthermore, this ratio was about 1:1 in both GSCs, thus suggesting that these cells are an 
efficient source of S1P in the extracellular microenvironment.  
Importantly, the S1P detection in GSCs medium was not accompanied by LDH release, demonstrating that 
the presence of S1P extracellularly was not a consequence of cell membrane rupture. 
The differences in the extracellular S1P levels between U87-MG and GSCs resulted also in a ceramide-
extracellular S1P ratio at least about 2-fold lower in GSCs than in U87-MG. Since S1P and ceramide exert 
opposite effects on cell survival, according to the “sphingolipid rheostat” model [111], this different ratio could 
promote GSC survival observed after TMZ treatment. 
We then hypothesized that the relevant amount of S1P in GSCs medium could be consequent to SKs 
secretion in the extracellular milieu, as it occurs in some cell types [167-169]. However enzyme activity 
assays led us to exclude the presence of SKs in the GSC medium, suggesting that extracellular S1P derives 
from the export of newly synthesized intracellular S1P and that protein-mediated transport mechanisms are 
most probably involved in the S1P export from GSCs.  
In this context, we analyzed in U87-MG and both GSCs the expression of ABCG2, ABCA1 and ABCC1, the 
members of the ABC-transporters family known to be involved in S1P export [173]. None of the analyzed 
transporters appeared to be expressed in GSCs, except for ABCA1. Data obtained by inhibiting this 
transporter in GSCs showed no significant variations in S1P release, thus leading us to exclude ABCA1 
involvement in S1P export. In future studies it will be interesting to characterize the precise transport 
mechanism responsible for the extracellular release of S1P by GSCs. 
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A further interesting finding of our study is that GSCs treated with TMZ and then pulsed with tritiated 
sphingosine show a 40% increase in extracellular [3H]-S1P levels in comparison with their untreated 
counterparts. On the other hand, no ceramide variations were observed after TMZ treatment, in agreement 
with the data obtained in T98G cells resistant to TMZ. This evidence leads us to hypothesize that GSCs are 
able to raise their extracellular S1P levels to protect themselves from the cytotoxic effect of TMZ regardless 
ceramide levels variations.  
Since U87-MG were sensitive to TMZ and characterized by markedly lower levels of extracellular S1P with 
respect to GSCs, we then analyzed the putative S1P role in TMZ-induced toxicity in U87-MG cells. We found 
that exogenously administered S1P was able to significantly prevent TMZ-induced cell death, determining a 
2-fold increase in viable cell number, compared to cells treated only with TMZ. These results demonstrated 
that exogenous S1P protects U87-MG cells against TMZ cytotoxic effect, contributing to their survival. 
Stimulated by these findings and by the efficient ability of GSCs to product extracellular S1P, we then 
investigated the putative role of S1P in GSCs resistance to TMZ. First we demonstrated that the inhibition of 
S1P synthesis, through a SK inhibitor, made both GSC models sensitive to TMZ toxicity. Furthermore 
exogenous S1P reverted the cytotoxic effect of the concomitant treatment with TMZ and SK inhibitor. These 
data strongly support extracellular S1P as an important mediator in TMZ-resistance of GSCs. 
In parallel, in order to better clarify S1P role in determining GBM aggressiveness from a clinical point of view, 
we analyzed S1P production in GSCs isolated from two patients affected by GBM with different aggressive 
phenotype and prognosis. Our preliminary data show that GSCs isolated from the patient with the most 
aggressive GBM were able to release an amount of S1P at least 4 times higher than those from the other 
patient. These results suggest that GSC extracellular S1P could have a peculiar role in determining GBM 
aggressiveness and patient prognosis. It will be interesting to evaluate extracellular S1P contribution in a 
higher number of GBM patients, in order to better verify our hypothesis. 
 
Altogether these data implicate, for the first time, GSCs as an important S1P source in the extracellular 
microenvironment, where, on its turn, S1P can act as an autocrine/paracrine messenger able to contribute to 
the GSCs aggressiveness and survival properties. In particular, the presence of S1P in the extracellular 
environment promotes GSC survival and resistance after TMZ treatment. Furthermore, the inhibition of S1P 
synthesis, and thus the reduction of its release, makes cells sensitive to this chemotherapic agent.  
Moreover, our findings provide a possible rationale for the results of a very recent study on FTY720, a 
sphingosine analogue that, once phosphorylated by SKs, initially activates S1P
 
receptors via high-affinity 
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binding, inducing subsequently their down-regulation [246]. Estrada-Bernal and colleagues in this study 
demonstrated that the in vitro administration of FTY720 decreases GSCs viability and acts synergistically 
with TMZ. Moreover, in vivo FTY720 promotes survival in a rodent model of GBM and decreases GSCs 
invasiveness in nude mouse brains. Taken together these and our results let us to speculate that S1P is 
efficiently produced within GSCs and, once released, acts through its receptors determining drug-resistance 
and promoting growth and invasion of GSCs, thus contributing to glioblastoma malignancy.  
A better understanding of S1P role in determining GSC malignant properties and its mechanism of action 
could help to identify new targets for the development of new therapies that may be associated with 
chemotherapy treatments already in use. Therefore, this study not only sets the basis for a greater 
comprehension of the mechanisms regulating GSC behavior, but also for the future development of efficient 
and effective therapies against GBM such as new compounds able to modulate S1P metabolism to strongly 
sensitize GSCs to chemotherapeutic treatments, thus improving survival rates and ensuring a long-term life 
perspective in GBM patients. 
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